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DNA methylation is an epigenetic modification known to be essential 
for normal development. Inappropriate regulation of DNA methylation can 
cause abnormal silencing of tumor suppressor genes leading to cancer. Despite 
the importance of this mechanism in human health, our existing knowledge is 
restricted to gene promoters and CpG islands (CGIs) which were thought to be 
key regulators of epigenetics. However, with less than 7% of CpGs located 
within CGIs, many CpGs remain uninvestigated resulting in a highly 
fragmented view of the epigenome. Here, I applied whole genome bisulfite 
sequencing (WGB-seq) to detect genome wide DNA methylation at single base 
pair resolution. Using this technique, I present the differential methylation 
changes during human embryonic stem (hES) cell differentiation and colorectal 
cancer (CRC) progression. I show that integrative analysis of the differentially 
methylated regions with gene expression profiles can identify candidate 
methylated genes involved in cell differentiation and CRC.   
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Chapter One: DNA methylation and human health 
Introduction 
 
The human body is made up of trillion of cells with specialized lineage 
and function. Each cell in an individual person contains the same genetic 
material hence, what influences or determines a cell from specializing into a 
muscle, liver or heart cell?  
 
In 1950s, Conrad Waddington first introduced the term “Epigenetics”, 
to describe different developmental changes that were brought about through 
the interactions between genes and their products (Waddington 1957). Since 
then the term had been redefine as the study of stable heritable phenotype 
changes without alteration in DNA sequences (Feinberg and Tycko 2004; 
Berger et al. 2009; Riddihough and Zahn 2010). Over the past 40 years, the field 
of epigenetic modifications had been well documented to be involved in 
alterations of the cellular phenotype through mediating gene regulation for 
normal development, differentiation, cell lineage commitment and maintaining 
cellular homeostasis (Rougier et al. 1998; Hemberger et al. 2009; Li 2013). The 
epigenome comprises of three types of modifiers including: DNA methylation, 
histone modification and non-coding RNAs (ncRNAs). DNA methylation 
involves the addition of methyl group (CH3) to carbon-5 of the cytosine 
pyrimidine ring predominately located within a CpG (cytosine-guanine) 
dinucleotide. The resulting methyl group can turn on or off the genes by 
affecting the interaction between DNA and the transcription machinery. The 
second type of modification involve post-translational histone modifications 
which include acetylation, methylation, phosphorylation, ubiquitination and 
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others (Hassan et al. 2002; Ray-Gallet and Almouzni 2010). The presence of 
different post-translational histone modifications alters the interaction between 
histone and DNA which affects the accessibility of the transcriptional 
machinery to the DNA (Ray-Gallet and Almouzni 2010). For instance, binding 
of histone H3K4 trimethylation (H3K4me3) to DNA alters the chromatin 
structure from ‘close’ to ‘open’ allowing the transcription machinery to bind 
DNA for active transcription. In contrast, the binding of histone H3K27 
trimethylation (H3K27me3) alters the chromatin structure from ‘open’ to 
‘close’ structure blocking the accessibility of  DNA which lead to inactive 
transcription (Zhao et al. 2007). The third type of modifiers, ncRNAs include 
microRNAs (miRNAs) and long ncRNAs (lncRNAs). For example, miRNAs 
can silence a gene through mRNA degradation by binding complementary to 
the target mRNA to prevent translation (Costa 2008). 
 
Overview of DNA methylation 
 
Among the three epigenetic modifications, DNA methylation is the most 
characterized and known to play essential roles in regulating normal mammalian 
development including imprinting and X chromosome inactivation (Li et al. 
1993; Heard et al. 1997; Reik et al. 2001). In DNA methylation, the process of 
methyl group addition to the cytosine is catalyzed by DNA methyltransferases 
(DNMTs). These DNA methylation activities can be further divided into either 
maintenance methylation (DNMT1) or De novo methylation (DNMT3A and 
3B). In maintenance methylation, the activity is catalyzed by DNMT1 to 
preserve and copy the DNA methylation patterns to the daughter strands during 
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DNA replication. It was demonstrated in a mouse model with genetically 
disrupted DNMT1 that the mouse showed genome wide loss of DNA 
methylation which resulted in embryonic lethality at day 10.5 post coitum (Li 
et al. 1992). This demonstrates the importance of maintenance methylation for 
normal embryonic development. In contrast, de novo methyltransferases which 
involve DNMT3A, 3B, and 3L is required for cell type specific DNA 
methylation patterns (Okano et al. 1999).  
 
In mammals, about 1% of the genome is made up of non-randomly 
distributed CpGs dinucleotides (Jones 1999), out of which 70-80% of the CpGs 
are methylated (Saxonov et al. 2006b). The regions with enriched CpGs 
dinucleotides are called CpG islands (CGIs), which is made up of short DNA 
sequences between 200-500 base pairs (bp) with more than 50% CG content 
(Gardiner-Garden and Frommer 1987). In addition, CGIs are commonly located 
near the 5’ end of annotated genes (Bird et al. 1985). Interestingly, the CGIs 
overlap with 60-70% of gene promoters where these genes in normal cells are 
protected from DNA methylation (Saxonov et al. 2006a; Weber et al. 2007). 
Hence, the promoter hypomethylation is a landmark of many ubiquitously 
expressed housekeeping genes that are essential for normal cell maintenance. In 
addition, the status of DNA methylation can be rapidly altered through either 
genome wide or gene specific active demethylation during distinct 
developmental stages or in response to environmental stimuli (Monk et al. 1987; 
Bruniquel and Schwartz 2003). Therefore, the regulation of the DNA 
methylome is highly dynamic which lead to the unique DNA methylation 
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patterns present in different cell types (Li et al. 1993; Esteller 2008; Pogribny 
and Beland 2009).  
 
DNA methylation and development 
 
During development, upon the formation of the zygote the genome 
progressively undergoes demethylation to remove methylation marks inherited 
from the gametes, this lead to chromatin decondensation and transcription 
activation which facilitated the reprogramming of the genome. As the cells 
undergo differentiation and lineage specification, DNA methylation patterns are 
re-established. Once established, the patterns remain unique in different somatic 
cells and stays stable during the adult life (Mayer et al. 2000). Therefore, 
selecting the right genes for expression and silencing the unessential genes is 
extremely crucial for normal development (Figure 1). In embryonic stem (ES) 
cells, transcription factors (TFs) such as POU5f1 and NANOG involved in 
pluripotency maintenance had been found to be selectively silenced by DNA 
methylation through promoter hypermethylation during differentiation (Deb-
Rinker et al. 2005). The presence of DNA methylation impacts the binding of 
TFs to their corresponding cis-regulatory elements affecting chromatin 
accessibility (Bird 2002). Thus, it is clear that DNA methylation plays critical 
roles in establishing proper transcription programs leading to cellular 




Figure 1. DNA methylation involvement in cellular development. 
The mammalian genome undergoes large scale DNA demethylation after zygote 
formation to remove the methylation marks inherited from the gametes to facilitate 
reprogramming. As cells differentiate they lose pluripotency and commit to different 
cell lineages to give rise to the unique cell types by re-establishing the DNA 
methylation patterns. Once established the DNA methylation patterns remain stable 
throughout the adult life of the cells.  
 
DNA methylation and cancer 
 
On the other hand, dysregulation in DNA methylation has been linked 
to pathological diseases such as Rett Syndrome and cancer (Bienvenu et al. 
2000; Sharma et al. 2010). In particular, in cancer cells global loss of DNA 
methylation was observed in colon cancer compared with normal colon 
(Feinberg and Vogelstein 1983) where loss of DNA methylation was associated 
with CpGs within the repetitive sequences of DNA including long interspersed 
elements 1 (LINE1) and satellite repeats. Such global DNA hypomethylation 
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events lead to genomic instability contributing to cancer development (Laird et 
al. 1995). In cancer, apart from global DNA hypomethylation, CGI promoters 
normally unmethylated in normal cells acquire aberrant DNA hypermethylation 
distorting the normal DNA methylation distribution (Feinberg 2004). For 
instance, classic tumor suppressor genes including WIF1, APC and RASSF2A 
are hypermethylated preventing the genes from carrying out their normal 
functions in regulating cell adhesion, cell migration and cell growth (Arnold et 
al. 2004; Taniguchi et al. 2005; Lee et al. 2009). Such aberrant DNA 
hypermethylation is a common hallmark of silencing tumor suppressor genes 
which contribute to cancer formation through transcriptional repression 
(Feinberg and Vogelstein 1983; Esteller 2007; Jones and Baylin 2007; Esteller 
2008).   
 
Unlike genetic mutations, DNA methylation modifications can occur in 
early stages of cancer and more importantly the modifications can be reversed 
which further highlights their clinical relevance (Verma and Srivastava 2002). 
For instance, GSTP1, an enzyme part of the glutathione-S-transferases (GST) 
superfamily in normal cells protects the DNA from oxidative damage by 
detoxification of carcinogens through glutathione conjugation. However, in 
prostate cancer this gene is often hypermethylated at the promoter leading to 
gene silencing and loss of GST expression (Jerónimo et al. 2002). In particular, 
a study conducted by Hashad and colleagues detected 24% (12 out of 50) of 
patients with benign prostatic hyperplasia, 60% (12 out of 20) of patients with 
prostate intraepithelial neoplasia and 86% (37 out of 44) of patients with 
prostate adenocarcinoma having GSTP1 promoter hypermethylation (Hashad et 
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al. 2011). This demonstrated that promoter hypermethylation is a common 
molecular alteration in prostate cancer which can be used as a biomarker for 
diagnostic purposes. In addition, a recent study showed that GSTP1 
hypermethylation can be reversed by treatment with histone deacetylase 
(HDAC) inhibitors such as depispeptide. Depispeptide reversed DNA 
hypermethylation of GSTP1 by inducing histone acetylation and reducing the 
binding of DNMT1 to the promoter region thus, allowing re-expression of 
GSTP1. It was further demonstrated that prostate cancer cell lines treated with 
depispeptide had increased apoptotic cells (Hauptstock et al. 2011). Therefore, 
understanding and comparing the DNA methylation regulation mechanisms in 
normal and disease condition can provide insights to disease development. 
Accurate characterization of DNA methylation patterns in different cell states 
can further identify key epigenetically regulated genes which can be used as 
biomarkers for clinical diagnosis or prognosis. In this thesis, I combined 
traditional bisulfite sequencing with next generation sequencing to characterize 
the dynamic changes in DNA methylation in normal and disease states to 
unravel the role of methylation at different genome features and identify key 
methylated genes involved in development and disease progression.   
 
Molecular approaches to enrich or label DNA methylation  
 
Given the importance of DNA methylation in human health many 
molecular techniques have been developed over the years. These molecular 
approaches can be classified into three categories: (1) enzymatic digestion, (2) 
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affinity purification and (3) chemical treatment, each with its own sets of 
limitations and advantages which I will discuss further in the following section:  
 
Enzymatic digestion based 
 
The use of restriction enzymes (REases) is a simple and direct method 
for detecting DNA methylation status. The technique uses REases which 
contain natural methylation sensitive or insensitive properties to the presence of 
methyl groups in their recognition sequences to detect CpG methylation (Bird 
and Southern 1978). Since DNA methylation occurs predominately at the 
cytosine within CpG dinucleotides, isoschizomers such as HpaII and MspI 
which share the same recognition sequences ‘CCGG’ but are methylation 
sensitive and insensitive, respectively, were most widely used to enrich 
methylated DNA (McClelland et al. 1994) (Figure 2A). After digesting the 
DNA with the specific REases, the DNA methylation patterns can be revealed 
by coupling the DNA with gene-specific analysis like PCR or traditional DNA 
sequencing across the restriction sites. It can also be coupled to genome-scale 
approaches such as array hybridization (Estecio et al. 2007; Omura et al. 2008) 
or next generation DNA sequencing (NGS) technology for large scale CpG 
methylation detection (Meissner et al. 2008; Brunner et al. 2009).   
 
Although a straightforward method, this approach lacks genome-wide 
coverage and is restricted to identification of DNA methylation at the REases 
recognition sites. Hence, to increase the genome coverage, REase cocktails 
combining different recognitions sites were used to detect the methylated CpGs. 
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However, such an approach can risk over fragmentation of the genome. By 
design, the REases used in the methods enriched for genomic regions that 
contained CpG dinucleotides hence, majority of the captured regions were 
located within CGIs or promoters. Therefore, this method is unsuitable for 
studies which require de novo detection of DNA methylation in non-CpG 
context. For instance, the detection of 5-methylcytosines (5mCs) in plant 
genome which can occur in mCHHs and mHCs (H= A, T, C, G) sequence 
context (Lister et al. 2008).  
 
Affinity purification  
 
In the affinity-based approach, the method uses either the principles of 
immunoprecipitation or affinity-based capture to selectively enrich methylated 
DNA. Among the different affinity based agents, methylated DNA 
immunoprecipitation (MeDIP) and methyl-CpG binding domain-based capture 
(MBDCap) are the most widely used (Weber et al. 2005; Brinkman et al. 2010). 
Unlike RE based techniques which are limited to CpGs detection at the RE 
recognition sites, MeDIP uses anti-5mC antibody to enriched for methylated 
DNA in the genome regardless of their sequence contexts. By coupling the 5mC 
enriched DNA with DNA microarray, the human methylation profile can be 
detected at 80 Kilobase (Kb) resolutions for up to 6,000 CGIs which has been 
applied to identify differential methylated regions in normal colon and 
transformed colon cancer cells (Weber et al. 2005). In contrast, MBDCap which 
uses MBD protein such as MBD2 to enrich methylated DNA is restricted to 
detection of 5mCs within the CpG dinucleotides (Figure 2B), hence this 
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approach is not applicable for detecting non-CpG methylation such as CpA 
methylation or CpT methylation. Nevertheless, MBDCap gives higher overall 
enrichment in particular at CpG-dense regions (Robinson et al. 2010). Although 
these methods are highly robust and efficient, they are biased towards high CpG 
density and sensitive to copy number variation, most importantly unable to 





Chemical based treatment using sodium bisulfite is an unbiased method 
for DNA methylation enrichment and thus regarded as a gold standard for DNA 
methylation studies (Clark et al. 1994; Clark et al. 2006). In bisulfite 
conversion, unmethylated cytosine (C) is converted into cytosine sulphonate 
through sulphonation by adding a sulfur trioxide group. The cytosine sulphonate 
is deaminated into uracil sulphonate and eventually converted into uracil (U) 
through rasemoval of the sulfur trioxide group while methylated C is protected 
from sulphonation hence, remains unchanged after bisulfite treatment (Figure 
2C). Upon PCR amplification, the U base is replaced by thymine (T). 
Methylated C which is resistant to bisulfite conversion can be differentiated 
from the unmethylated C (converted to T) through DNA sequencing. Therefore, 
complete bisulfite conversion is extremely critical to prevent false positive 
detection of unmethylated Cs. In recent years, bisulfite treatment was combined 
with REs digestion (reduced representation of bisulfite sequencing; RRBS) to 
reduce sequencing complexity and cost. In RRBS, DNA is first digested with 
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MspI a methylation insensitive restriction enzyme followed by sodium bisulfite 
treatment and subjected to NGS for methylated CpG detection (Meissner et al. 
2008; Gu et al. 2010) (Figure 2D). Using RRBS, the first genome wide mouse 
ES methylome was completed, at least 1 million distinct CpG dinucleotides 
(~4.8% of all CpGs in the mouse genome) were examined. It was revealed that 
high CpG density promoters (HCPs) were associated with ‘housekeeping’ genes 
and ‘developmental’ genes where ‘housekeeping’ genes were highly enriched 
with transcription initiation mark H3K4me3 and ‘developmental’ genes were 
enriched with both H3K4me3 and repressive histone mark H3K27me3 termed 
bivalent regions (Meissner et al. 2008).      
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Figure 2. Overview on molecular technologies to enrich or label 5-
methylcytosines. 
(A) Enzymatic based approach using isoschizomers MspI and HpaII to digest 
methylated DNA and unmethylated DNA, respectively. (B) Affinity based approach 
using 5-methylcytosine (5mC) specific antibody to enrich DNA fragments containing 
5mC in any sequence context. Alternatively, methyl-binding protein (MBD) had been 
used to enrich methylated DNA. However, only fragments containing methylated CpGs 
will be enriched. (C) Bisulfite conversion of unmethylated cytosine to uracil through 
three main processes: Sulphonation, hydrolytic deamination and alkali desulphonation. 
(D) RRBS approached which uses restriction enzyme, MspI, together with bisulfite 
treatment for genome wide detection of methylated CpG. Note: Diagram was adapted 




Overview of technologies for DNA methylation detection  
 
 In order to discriminate the methylated and unmethylated Cs in the 
genome, various technologies of different scales have been developed. For 
instance, small scale locus-specific analysis via two dimensional electrophoresis 
(Costello et al. 2000) and PCR amplification (Yamada et al. 2004) and large 
scale using array-based hybridization (Schumacher et al. 2006) or sequencing 
(Rollins et al. 2006). In recent years, NGS technologies were adapted for 
system-wide epigenome studies (Zhao et al. 2008; Fullwood et al. 2009) for 
histone modification mapping, chromatin interactions and DNA methylome 
profiling. With sufficient base coverage, methylation sequencing is able to 
decipher the whole genome methylome at single-base resolution even in 
complex mammalian genomes. Here, I will focus on two large scale detection 
methods, their associated technical specificities and issues including coverage, 




 The array hybridization detection method can yield DNA methylation 
profiles from bisulfite-treated DNA at base pair resolution. However, in order 
to distinguish the unmethylated from methylated Cs, hybridization of the 
amplified bisulfite-converted DNA onto  the microarray requires special 
consideration on probe design as well as the data analysis methods (Reinders et 
al. 2008). One such detection method is the Illumina Infinium 
HumanMethylation27K BeadChip method (Illumina, Inc.). In this approach, 
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two versions of site-specific probes, one to detect methylation and the other to 
detect unmethylation were used to perform multiplexed primer extensions on 
bisulfite-treated DNA. A fluorescent ddNTP substrate is incorporated with each 
single base extension and the fluorescent intensities emitted from the probes are 
measured. The relative ratio of fluorescent hybridization signals from the 
methylated C and unmethylated T probes provide a quantitative methylation 
measurement for each interrogated CpG locus (Bibikova and Fan 2009) (Figure 
3A). The current capacity of HumanMethylation27K BeadChips allow parallel 
profiling of 27,578 CpG sites from 14,495 human Refseq gene promoters. Such 
coverage has since been extended to more than 450,000 sites in the Infinium 
HumanMethylation450 BeadArray, which cover CpGs beyond CGIs and 
promoters, as well as non-CpG sites. Compared to the sequencing approach, 
array-based methods offer superior sample multiplex capability, but suffer from 
potential bias resulting from hybridization noise. Although the method allows 
single-base resolution detection, it is limited to studies of methylome from 
species with commercially-available methylation arrays. Therefore, this 




Recent advancement in high-throughput (HTP) DNA sequencing 
enabled the direct mapping of DNA methylation on next-gen platforms such as 
HiSeq (Illumina) and SOLiD (Life Technologies) (Lister et al. 2009; Bormann 
Chung et al. 2010; Laurent et al. 2010; Li et al. 2010b). NGS technologies can 
be coupled with RE-based (Methyl-seq), affinity-based enrichment (MeDIP-seq 
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and MBDCap-seq) and chemical based for direct whole genome bisulfite 
sequencing (WGB-seq) to decipher the genome wide methylation profiles. 
Among these, WGB-seq remained the most powerful method for global single 
nucleotide resolution profiling of DNA methylome with high accuracy and 
reproducibility (Li et al. 2010a) (Figure 3B). The method was first performed 
in small genomes such as Arabidopsis thaliana (Cokus et al. 2008; Lister et al. 
2008) but had since expanded to handle large complex mammalian genomes 
including mouse and human (Lister et al. 2009; Laurent et al. 2010; Li et al. 
2010b).  
 
Compared with array-based analysis, sequencing-based methylome 
assays can be applied to any species so long as the reference genome sequences 
are available, providing the flexibility for either target specific or whole-genome 
scale detection. The dynamic range for sequencing detection can be adjusted to 
increase sensitivity by increasing the sequencing depth, which is specifically 
useful in resolving hemi (methylated on one allele) from the fully-methylated 
CpGs. The resulting hemi-methylation information through linking with cis-
strand SNPs will allow the identification of allele-specific DNA methylation 
(ASM), which cannot be determined by array-based methods. In summary, 
different sample enrichment methods and detection approaches have distinct 
technical specificity and unique advantages (Table 1) (Wong and Wei 2011). 
To date, WGB-seq remains the most comprehensive and dynamic approach for 
high-resolution DNA methylome profiling which enables the detection of more 
than 90% of total cytosines (Cs) (Laurent et al. 2010). Future advances will rely 
on the development of sophisticated bioinformatics tools, to understand the 
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impact of various methylation profiles on other genomics/epigenomics 
regulation and to integrate them with other genome-wide knowledge. 
 
Figure 3. Overview of large scale DNA methylation detection technologies. 
(A) Array-based DNA methylation detection involved the hybridization of enriched 
methylated DNA either through sodium bisulfite or RE digest onto the microarray chip 
pre-coated with more than 10, 000 probes representing different CpG sites in the 
genome. The chip is scan to record the fluorescent intensities emitted by the labeled 
probes in the event of DNA and probe binding. The intensities obtained are normalized 
against the background to detect the rate of DNA methylation of a particular CpG site. 
(B) Methylated DNA can be subjected to NGS using either Illumina platform through 
sequencing by synthesis technique or SOLiD ligation based sequencing for large scale 
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Table 1. Overview of various methylation detection and enrichment methods. 
a: Each detection method capacity for multiplexing and data throughput is rated by the number of '+'. b: Indicates the capability of each detection methods in 
identification of non-5mC methylation such as 5-hydroxymethyl-cytosine and N6-methyladenine. Table was adapted from (Wong and Wei 2011).
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Proposal: Understanding the dynamics of DNA methylation through 
WGB-seq 
 
Proper gene regulation is required for normal development and 
maintenance of cell identity. Derangements in DNA methylation can lead to 
alterations in gene expression in cancer cells, resulting in downregulation of 
tumor suppressor genes by DNA hypermethylation (Akino et al. 2005; 
Shames et al. 2006; Ting et al. 2006; Kim et al. 2009). Thus, understanding 
the regulation of DNA methylation and its involvement in gene expression 
alterations becomes an important stepping stone for us to decipher cellular 
and disease development.    
 
In 2008, Meissner and colleagues used the RRBS-seq approach to 
generate a reduced representation DNA methylation map in mouse ES cells 
which covers CGIs containing a representative sampling of conserved non-
coding elements and transposons (Meissner et al. 2008). Although RRBS-seq 
analysis has limited coverage and is biased towards the detection of CpGs within 
the enzyme recognition site, this study has already shown that DNA methylation 
occurs extensively throughout the genome and is highly dense in the 
heterochromatin regions and prevalent in both the promoters and gene body 
regions. Increased resolution of the genomic methylation maps not only reveal 
cell type-specific differential methylation (Deng et al. 2009) but also discovered 
that expressed protein-coding genes in general had lower DNA methylation 
levels around their promoter region and higher DNA methylation levels over 
their gene body (Ball et al. 2009). More recently, genome wide bisulfite studies 
at single base resolution in Arabidopsis thaliana revealed that DNA methylation 
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is not only found in the promoter CGIs but can also be found within transcribed 
regions of many endogenous genes in different sequence contexts (Cokus et al. 
2008; Lister et al. 2008). In human, methylation at CpG sites located at the 
edges, or "shores," of promoter-associated CGIs has been inversely correlated 
with gene expression (Irizarry et al. 2009). Together, these studies demonstrate 
that with increased resolution, new and subtle phenomena can be revealed, 
providing new insights into the mechanisms by which cells regulate gene 
expression. The current efforts on how DNA methylation influences other 
genomic features is largely focused at either selected loci or specific regulatory 
regions, i.e. promoters, CGIs or transcription factor binding sites (TFBS) 
(Meissner et al. 2008; Straussman et al. 2009b; Straussman et al. 2009a). Thus, 
the genome wide distribution of DNA methylation remains unclear; how DNA 
methylation is affected by local sequence context, how it changes during cellular 
differentiation and what is the global impact of DNA methylation on gene 
activity and other epigenetic modifications are yet to be answered. 
 
To address these questions, we propose to perform whole genome 
bisulfite sequencing (WGB-seq) which involve coupling of sodium bisulfite 
treatment with NGS technologies to characterize the genome wide methylation 
maps of normal cellular differentiation and cancer progression using human 
embryonic stem cells (hESCs) and colorectal cancer (CRC) as our study models. 
Our large scale comparative methylome assays shall; (1) provide the complete 
human methylome maps during normal and disease states. (2) Allow the 
elucidation of the effects of DNA methylation on gene expressions at various 
genomic features including the gene promoters, gene body, exons, introns and 
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intergenic regions. (3) The correlation of DNA methylation with other 
epigenetic modifiers. (4) Lastly, locate distinct differentially methylated regions 
(DMRs) and their associated genes which may be potentially involved in 
regulating hESCs differentiation and CRC development. Hence, the established 
high resolution hESC and cancer epigenome maps shall shed light on how DNA 
modifications and gene expression regulations are involved in normal and 
disease development.   
 
Construction of WGB-seq libraries  
 
The principles of WGB-seq involved the coupling of bisulfite 
conversion with NGS technologies to achieve genome wide DNA methylation 
coverage at single nucleotide resolution. To construct a WGB-seq library, 
purified genomic DNA (gDNA) was randomly sheared into fragments between 
300 bp to 800 bp using nebulization, instead of restriction enzymes in methods 
such as RRBS and Methyl-seq (Meissner et al. 2008; Brunner et al. 2009). In 
nebulization, pressured nitrogen gas was used to perform the random DNA 
shearing. The DNA sizes can be controlled by the gas pressure and time of 
exposure. The higher the gas pressure and the longer exposure time generate 
smaller DNA fragments. In order to ensure the template is compatible for 
downstream sequencing, DNA is first end polished followed by addition of an 
‘A’ base to the 3’ end of the DNA to complement the ‘T’-overhang present in 
the paired end (PE) sequencing adapters (Illumina). Given bisulfite treatment 
converts unmethylated C to T and results in single stranded (ssDNA). To 
counter this issue, the PE sequencing adapters were modified to have all Cs in 
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the adapter sequences synthetically methylated to prevent the unmethylated Cs 
from being converted to Ts during bisulfite treatment and the modified 
methylated PE adapters were ligated to both ends of the DNA before bisulfite 
treatment. To ensure sufficient DNA template for sequencing, PCR 
amplification was performed using the PE PCR sequencing primers. NGS 
technologies such as Illumina Genome analyzer (GA) are known for their 
limited readlength hence, the amplified PCR product had to undergo size 
selection in 2% agarose gel to obtain fragments between 250-350 bp before PE 
sequencing on Illumina Genome analyzer (GA) with readlength up to 2X 101 
bp (Figure 4). 
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Figure 4. Schematic overview of the whole genome bisulfite sequencing at single 
base resolution using Illumina PE sequencing. 
Purified genomic DNA was subjected to random shearing using nebulization into 
DNA fragments between 300-800 bp. The fragmented DNA was end polished, 3’ A-
tailed and ligated with methylated PE sequencing adapters on both ends of the DNA. 
The DNA was chemically treated with sodium bisulfite to convert unmethylated Cs 
to Us. Upon PCR amplification, the Us were converted to Ts. Gel size selection of 
fragments between 250-350 bp was performed before subjecting to PE sequencing 
using Illumina GA up to readlength of 100 bp.  
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Sequencing analysis of whole genome DNA methylome 
 
Prior to NGS, large scale genome wide DNA methylation analysis is 
dependent on either DNA microarray or Sanger sequencing each with its own 
sets of disadvantages (Birney et al. 2007). For instance, DNA microarrays 
require prior knowledge of the target region before oligos probes can be 
designed. Furthermore, the designed probes are unable to cover all the Cs in 
complex genomes such as the human genome. Therefore, the method prevented 
the discovery of novel methylation patterns. While, traditional Sanger 
sequencing which uses dideoxy chain termination chemistry had the advantage 
of long readlength average of up to 800 bp, a single 384-well plate of readlength 
800 bp with an average mapping rate of 70% only generates 215, 040 bp per 
sequencing run. Thus, to obtain 1X human genome coverage, an estimate of 14, 
000X 384-well plates need to be sequenced which is extremely costly and highly 
time consuming (Liu et al. 2012).  
 
Nevertheless, recent advances in NGS technologies had largely 
increased the sequencing throughput producing over 500 million reads with 
readlength up to 100 bp within 7 days (Liu et al. 2012). Thus, whole human 
genome 5mC detection at single nucleotide resolution is now possible. Despite 
the HTP, NGS technologies are limited by their short readlength (< 100 bp) and 
high error rates accumulating towards the end of the sequencing reads (Wold 
and Myers 2008). In NGS technologies, a single read (SR) sequencing (SR-seq) 
only sequenced up to the first 76 bp of the 5’ end of a PCR template. In contrast, 
a PE-seq sequences both the 5’ and 3’ end of a PCR template with readlength 
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up to 100 bp. Hence, by analyzing the PE reads independently one will be able 
to interrogate the Cs within the first and last 100 bp of a DNA fragment which 
increased the total reads and hence, reduces the overall cost of sequencing.  
 
Among the NGS technologies, Illumina sequencer and SOLiD (Life 
Technologies) are the most popular. Illumina uses sequencing by synthesis 
(SBS) chemistry while SOLiD platform uses ligation-based chemistry. Briefly, 
in the SBS method, the sense strand of the DNA serve as a template for parallel 
base by base sequencing. Four fluorescence ddNTPs were added to the 
sequencing mixture simultaneously for natural competition. After every round 
of complete fluorescence ddNTPs incorporation, the excess ddNTPs will be 
cleaved and flushed out of the system. The fluorescence intensity emitted will 
be captured with each nucleotide represented by a unique color. In contrast, the 
sequencing by ligation chemistry involved a set of four fluorescently labeled di-
base probes with up to 16 dinucleotides competing for ligation during 
sequencing. Here, each base in the sample is interrogated by 2 different probes. 
With the 2-base encoding, the nucleotides are reported in color space instead of 
strings of nucleotides. As a result, post sequencing alignment of SOLiD reads 
required additional steps to convert the color space reads to base space before 
alignment to the reference genome (Bormann Chung et al. 2010). Although, 
alignment program such as SOCB-s and B-SOLANA are available for 
alignment of bisulfite treated color space reads (Kreck et al. 2012). The 
percentage of uniquely mapped reads and speed of alignment were 
unsatisfactory. For instance, alignment of 100,000 color space reads by the 
SOCB-s and B-SOLANA only gave a unique mapped rate of 28.3% to 37.4% 
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with a mapping speed ranging from 2 min and up to 71 hours in the case of 
SOCB-s (Lim et al. 2012). Given the inefficiency in the color space alignment 
and the in availability of SOLiD PE bisulfite library preparation, we thus 
decided to perform our WGB-seq on the Illumina platform. Using WGB-seq, a 
robust platform for methylome mapping, comparison between different 
methylome could soon unveil the dynamics of methylation patterns and 
complex levels of regulation. However, factors such as genome structure 
variations could have significant impacts on the relative profiles and 
differentially-methylated regions (DMRs) defined; particularly in regions 
subject to copy number variation (Robinson et al. 2010). Thus, proper controls 
with input DNA should be sequenced in parallel.  
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Mapping of WGB-seq libraries to the reference genome 
  
One of the major challenge of WBG-seq is the ability to align the 
bisulfite treated reads back to the reference genome for accurate detection of 
methylated cytosines (Cs). In the mammalian genomes, only about 3-6% of the 
cytosines are methylated hence, upon bisulfite treatment the majority of the 
unmethylated cytosines will be converted to T resulting in a three-base genome 
(T, A and G). With the reduced sequence complexity, the specificity of 
assigning bisulfite sequence reads to their corresponding reference genome 
using generic alignment programs is compromised. Additional challenges arise 
when the DNA is partially converted during bisulfite treatment. Hence, special 
computational solutions and bioinformatics tools are required to process the 
bisulfite sequencing data.  
 
To overcome the alignment issue, we converted both the WGB-seq reads 
and the reference genome into a three-base genome by preparing two converted 
reference genome; (1) In silico replacement of all Cs in the plus strand to Ts, to 
assume complete bisulfite conversion state, (2) and in silico conversion of the 
complementary minus strand guanines (Gs) with adenosines (As). (3) We then 
aligned the converted reads to their respective converted genome. Subsequently, 
filtering parameters were applied to remove reads reported with multiple 
alignment locations to obtain the unique reads (defined as reads with a single 
mapping location) for downstream analysis. Using the mapped locations, the 
converted reads were reverted and compared against the unconverted reference 
genome to identify and differentiate the methylated Cs from the unmethylated 
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Cs (Figure 5). Using this mapping strategy, we had significantly improved the 
mapping rate from 6% (unconverted reads to unconverted genome) to more than 
75% (converted reads to converted genome). See Chapter Two- Materials and 
method for detailed description of bisulfite read alignment.  
 
Figure 5. Overview of WGB-seq mapping strategy. 
 
Raw sequence reads generated from Illumina Genome Analyzer first undergo base 
calling and quality filtering. To increase mapping efficiency and compensate for 
incomplete bisulfite conversion, both sense strand of reference genome and filtered 
reads had their Cs converted to Ts, while anti-sense reference genome and filtered 
reads Gs were converted to As. The converted sense strand filtered reads were 
mapped to the sense strand reference genome and vice versa for the anti-sense strand. 
Reads that mapped to the converted genome with less than 2 bp mismatches were 
consolidated into a matched list. Reads from the matched list were reverted to their 
original read sequence and compared against the original reference genome to 
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5’ TCG…CCG…AT 3’ 5’ AT…CGG…CGA 3’
Convert all G to A
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Convert all C to T Convert all G to A
5’ TTG…TTG…AT 3’ 5’ AT…CAA…CAA 3’ 5’ TTG…TTG…AT 3’ 5’ AT…CAA…CAA 3’







Chapter Two: Investigating the dynamic changes in the human methylome 
during cell differentiation 
Introduction 
 
Human embryonic stem cells (hESCs) are pluripotent cells with self-
renewal properties which can give rise to most cell types in the body including 
the germ layers. This generated huge interest in recent years to understand the 
mechanisms involved in regulating the pluripotency and cell differentiation for 
future clinical interventions. Despite the importance of DNA methylation in 
lineage specification, little is known on how changes in DNA methylation 
profiles participate in cell differentiation. This is because existing DNA 
methylation pattern detection methods are largely biased toward CG-rich 
regions of the genome or limited in scale. For instance, the use of methylation-
sensitive restriction enzymes (Meissner et al. 2008) or affinity enrichment 
through 5mC specific antibodies (Cross et al. 1994; Weber et al. 2007). 
Nevertheless, these methodologies provided valuable snapshots of DNA 
methylation patterns in a variety of cell types and its correlation with gene 
expression. Hence, to further understand the complex human methylome and 
the impact of DNA methylation changes during cell differentiation, we 
combined WGB-seq together with bioinformatics analysis to generate single 
nucleotide resolution methylome maps of cells representing progressive stages 
of cellular differentiation; from undifferentiated hESCs to differentiated 
fibroblast (hESC-Fibro; a fibroblastic derivative of the hESCs) and a primary 
fibroblast, Fibro and compared our cultured cell types methylome maps to a 
terminally differentiated peripheral blood mononuclear cells (PBMC) 
methylome map (Li et al. 2010b).  
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Results 
Construction and mapping of WGB-seq libraries 
 
To establish the hES methylome map and investigate the methylation 
changes during cell differentiation, three WGB-seq libraries were constructed 
from hES, hES-Fibro and Fibro cells. Purified genomic DNA (gDNA) was 
extracted from the three cell lines and randomly sheared to obtain fragments 
between 300-800 bp. To make the DNA compatible with Illumina PE 
sequencing, the DNA was end repaired and 3’ A-tailed before ligating both ends 
of the DNA with the PE adapters. To prevent the unmethylated Cs in the PE 
adapters from being converted to Ts during bisulfite treatment, all Cs in the 
adapter sequence were modified to contain methyl groups to avoid C-T 
conversion. Upon bisulfite treatment, the converted DNA becomes single 
stranded which binds poorly to the double stranded pre-methylated PE adapters 
hence, we first ligated the methylated PE adapters to both ends of the 3’ A-tailed 
DNA before bisulfite treatment. In WGB-seq, one of the major challenges is the 
risk of incomplete bisulfite conversion whereby unmethylated Cs are not fully 
converted to Ts which can result in false positive 5mCs detection. To overcome 
incomplete bisulfite conversion and maximize the conversion efficiency, the 
duration of bisulfite treatment was increased by performing two consecutive 
rounds of the below cycling conditions; (99°C for 5min, 60°C for 25min, 99°C 
for 5min, 60°C for 85min, 99°C for 5min, 60°C for 175min) X 2. The bisulfite 
conversion efficiency was subsequently validated using bisulfite PCR (BSP) 
and Sanger sequencing before committing the libraries for large scale 
sequencing. PCR primers were designed to amplify selective gene regions 
known to contain CpGs methylation. Next, the PCR product was purified and 
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cloned into a TOPO blunt end plasmid vector followed by Sanger sequencing. 
For example, gDNA extracted from H9 cell line (hESCs used in this study) were 
treated in parallel to either 1X or 2X bisulfite conversions. The converted DNA 
was PCR amplified using primers surrounding 1529 to 1806 bp downstream of 
HCRTR1 transcription start site (TSS), a gene expressed in the hypothalamus is 
silenced in hESCs (Sakurai et al. 1998). The bisulfite conversion rate was 
calculated by taking the ratio of non-CpG C converted to T over the total number 
of non-CpG Cs. As CpGs dinucleotides are mostly highly methylated hence 
remain unconverted after bisulfite treatment, therefore the C from the CpG sites 
were excluded from the bisulfite conversion rate calculation. We found that 1X 
bisulfite conversion obtained an average of 97% conversion rate while 2X 
bisulfite conversion achieved near complete conversion >99% (Figure 6). Since 
a successful bisulfite conversion will result in most or all unmethylated C-U 
conversion, which upon PCR amplification will translate the U-T. To ensure all 
Us gets translated to Ts during PCR without stalling, we used PfuTurboCx 
Hotstart polymerase (Stratagene). This particular polymerase contained 
proofreading function and is able to read through long stretches of Us without 
interruption making it suitable for DNA methylation analysis. Lastly, 8-10 PCR 
amplification cycles was performed to minimize PCR clonal amplifications as 
well as to ensure sufficient material for sequencing. During bisulfite treatment, 
DNA is subjected to high temperature and high salt condition which can lead to 
DNA fragmentation. Therefore, the starting DNA material was sheared to larger 
fragments (300-800bp) but a final smaller insert size selection of 250-350 bp 
was performed. The final PCR product was subjected to PE-seq with readlength 
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up to 76 bp using Illumina GAIIx. Using this approach, we generated an average 
of 636 million reads for each WGB-seq libraries (hESCs, hES-Fibro and Fibro). 
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Figure 6. Sodium bisulfite conversion efficiency. 
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Bisulfite specific PCR was performed on hESCs subjected to 1X or 2X bisulfite (BS) 
treatment at Chr1:31857414-31857695. A total of 7 individual clones were sequenced 
from each treatment and aligned to the BS converted human reference sequence. The 
bisulfite conversion rate for each clone was calculated by taking the number of 
converted unmethylated Cs in non-CpG sites over the total number of Cs in non-CpG 
sites within the PCR region. The average conversion efficiency for 1X BS-treatment is 
>97% and 100% for 2X BS-treatment. The PCR forward and reverse primer sequences 
were marked in red, methylated CpGs in orange, unmethylated CpGs in purple and 
unconverted unmethylated Cs in non-CpG sites in blue.     
  
 
To identify the methylated cytosines in the genome, the bisulfite treated 
reads were first aligned onto the human reference genome, hg18, downloaded 
from UCSC genome browser using Short Oligonucleotide Analysis Package 
version 2 (SOAP2), a seed and extend alignment program (Li et al. 2009). In 
SOAP2, three major steps were involved: (1) Conversion of both bisulfite reads 
and reference genome to assume complete bisulfite conversion. (2) Align 
converted bisulfite reads to the converted genome to identify the potential 
mapping loci. (3) Return the converted reads and genome to the original form 
to discriminate the actual 5mC from the unmethylated C. Briefly, bisulfite 
treatment convert all unmethylated C-Ts. Thus, the plus and minus strand of the 
converted DNA is no longer complementary to each other. The individual 
converted plus and minus strand DNA each serve as a template for PCR. As a 
result, the final sequenced read can come from any of the four possibilities; (1) 
converted plus strand, (2) reverse complement (RC) of converted plus strand, 
(3) converted minus strand and (4) RC of converted minus strand. In order to 
map the converted reads back to the reference genome, in silico replacement of 
C-T was performed on the plus strand of both reads and reference genome. 
Followed by, replacement of G-A on the complementary strand. Given that the 
human reference genome is very large, direct mapping of the converted reads to 
the plus strand then mapping them to the RC genome will require high 
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computational power. Hence, the converted genome plus and minus strand were 
kept separately, while the short reads and its RC get mapped to the two reference 
genome. This way mapping can be completed faster using less computational 
power. In general, NGS sequencing tends to accumulate higher error rate 
towards the 3’ end of the read, hence an initial seed length of 36 bp with up to 
2 bp mismatches were used to align the reads to the genome followed by 
extending the readlength base by base until the maximum allowable length were 
aligned with less than 2 bp mismatches. Using the mapping loci as a reference 
point, both the bisulfite reads and the converted reference genome were reverted 
to their original form to distinguish the methylated Cs from the unmethylated.  
 
With the SOAP2 alignment program, 445 million reads were uniquely 
aligned to the human reference genome (hg18) at a mapping rate of ~70%. This 
gave us a median physical coverage of 10-12 reads per base. Here, a read is 
considered non-redundant when it maps to a unique location without sharing the 
same start and end location as another read. Through our analysis, our data was 
able to examine > 85% of all Cs in the genome and > 90% of Cs in CpG 
dinucleotides with at least 1 read coverage (Table 2). We accessed the 
methylation status of each detected Cs by calculating the number of reads called 
methylated Cs over the number of reads covering the C position. The 
methylation ratio was obtained by expressing the values continuously from 0-
100%. Based on the methylation ratio, each examined C was categorized into 
any of the following: (A) methylated (M: >80%), (B) intermediate between 
partially methylated and methylated (M_P: 60-80%), (C) partially methylated 
(P: 40-60%), (D) intermediate between unmethylated and partially methylated 
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(U_P: 20-40%) and (E) unmethylated (U: <20%). To verify our data processing 
and accuracy of our methylation calling strategy, we validated our WGB-seq 
data against an independent platform HumanMethylation27K BeadChip 
microarray (Methyl27K) (Illumina) using the same samples that were used to 
generate the WGB-seq libraries. Here, all CpGs with at least 1 read coverage 
detected in WGB-seq was used to compare against the CpGs detected in 
methyl27K assay. In Methyl27K assay, a total of 27,318 CpGs sites from 14,495 
promoter regions methylation status were investigated. The total CpG sites 
interrogated by the Methyl27K assay covers 0.1% of total CpG sites in the 
genome and 0.01% of the data generated by WGB-seq. On average, more than 
80% of the CpGs sites in Methyl27K assay were covered by WGB-seq. Among 
the covered CpGs sites 76% of the CpGs showed concordant methylation status. 
We further investigated the CpGs with non-concordant methylation status and 
found these CpGs (approximately 5,200) per sample to have low reads coverage 
(<3 reads coverage) (Table 3). Based on the above results to give an accurate 
estimation of the methylation status, we only used Cs with at least 3 reads 
coverage. By filtering Cs with less than 3 reads coverage, our WGB-seq data on 
average covered >70% of CpGs in the genome. To further increase the 
percentage of CpGs genome coverage to over 90%, it is estimated that a physical 







Library ID GHE002 GHN002 GHF002 
Sample 
name 




hESCs, H9 cell line 
Neonatal foreskin 
fibroblast 








6 5 6 
Sequencing 
run type 
PE 2X 76bp PE 2X 76bp PE 2X 76bp 






Pass filtered 858,141,016 63.2 958,424,656 69.8 816,830,044 63.4 
Mapped 523,457,901 34.1 595,846,336 37.3 507,178,044 35.4 
Mapping 
rate 




407,608,000 26 460,830,001 28 337,179,056 22.9 
Redundancy 28.4% 29.3% 50.4% 
Effective 
coverage 




98.5% 99.3% 99.2% 
% of C 
covered 
88.5% 89.8% 83.4% 
% of C 
within CpG 
covered 




57.4% 52.5% 58.5% 
Table 2. WGB-seq library sequencing and mapping statistics for hESCs, hESC-
Fibro and Fibro. 
On average, 445 million reads were uniquely aligned to the reference genome, giving 
an estimate of 9X genome coverage. The estimated bisulfite conversion rate is more 
than 99% and more than 85% of the total genome cytosines were covered by our WGB-




Table 3. Methylation calling data comparison between WGB-seq and 
methylarray27K array. 
 
The methylation status of CpG sites covered in both methylarray and WGB-seq were 
compared. On average more than 80% of the CpGs sites in detected in the array were 
also detected in WGB-seq. Among the covered CpGs, 76% of these CpGs showed the 
same methylation status. Cs with different methylation status in methylarray and WGB-
seq resulted from Cs with < 3 reads coverage. Note: Table was adapted from (Laurent 
et al. 2010).  
 
To determine if the hESC-Fibro cells used in this study is an intermediate 
between hESC and Fibro, whole genome gene expression profile using 5 
replicates of the 3 cell types was performed and compared against other hESC 
hESC
M M_P P U_P U Not covered
by WGB-seq
M 3149 940 449 114 433 1826
M_P 387 198 189 88 123 441
P 114 85 165 142 226 414
U_P 54 25 106 178 541 580








M M_P P U_P U Not covered
by WGB-seq
M 2335 215 116 32 109 1154
M_P 692 173 108 29 88 431
P 530 182 150 85 138 453
U_P 369 157 185 161 354 468








M M_P P U_P U Not covered
by WGB-seq
M 2423 567 439 253 665 1833
M_P 294 135 146 125 303 488
P 163 68 123 181 751 501
U_P 62 45 94 153 925 454




9.90E+06 1.75E+06 1.84E+06 1.34E+06 2.28E+08
77.55%
74.22%
%CpG in Methyl27K array covered by WGB-seq




























%CpG in Methyl27K array covered by WGB-seq
% covered CpG from both platforms with same methylation call
%CpG in Methyl27K array covered by WGB-seq
% covered CpG from both platforms with same methylation call
39 
and primary cell lines (Müller et al. 2008). The results were expressed in a 
dendrogram, based on the Pearson correlation scores the hES-Fibro cells were 
a unique cell type but contained overlapping genes between hESC and Fibro. 
This further confirmed hES-Fibro is an intermediate between hESCs and Fibro 
(Figure 7).   
 
Figure 7. Global gene expression data profile comparison between hESC, hESC-
Fibro and Fibro. 
High pearson correlation scores together with high number of overlapping genes 
between the hESC, hESC-Fibro and Fibro showed that hESC-Fibro is an intermediate 
of hESC and Fibro and that the 3 cell lines shared the same lineage. Note: Diagram 





Global profiling of the human methylome during cell differentiation and 
identification of the non-CpG methylation  
  
To present the first genome wide profile of the DNA methylation 
patterns at different cell differentiation states, we calculated the methylation 
status of every C position with at least 3 reads coverage for hES, hES- Fibro and 
Fibro alongside PBMCs as reference. Globally, we found that the majority of 
the Cs in the genome (92%-95%) were unmethylated in all 3 cell types. Among 
the four cell types, we observed that undifferentiated hESCs has the highest 
methylation levels (6%) while terminally differentiated PBMCs had the lowest 
methylation (3%). This suggested that there is a global reduction in DNA 
methylation distribution which is inversely correlated with differentiation status 
(Figure 8A).  
 
In mammals, DNA methylation has been known to be predominantly 
located within the CpG sequence context. However, with the single base pair 
resolution of WGB-seq we were interested to know if DNA methylation has any 
sequence specific context. We evaluated the relative prevalence of DNA 
methylation sequence context at -1, +1, and +2 positions relative to cytosines 
(HC, CH, and CHH: H= any of the four bases) for any base preference. Overall, 
at CH position the human cells were observed to contain strong preference for 
cytosine methylation in CpG context (>80%) compared to plants with only 55% 
of methylated cytosine residues in the CpG context (Lister et al. 2008). In 
comparison to techniques biased against regions with high CpGs content 
(RRBS), which detected 40% of the genome CpGs methylated and 20% 
unmethylated, our unbiased whole-genome approach revealed that 55% of the 
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genome CpGs were methylated (M ≥80%) and 20% were unmethylated (U 
≤20%) while the remainder 25% CpGs had partial methylation (20% <M_P 
<80%). The detection of higher percentage of methylated CpGs (mCpG) in our 
data showed the existence of higher level of methylated CpGs within low CpG 
density regions of the genome. Such observations were previously undetected 
in earlier studies that employed methods biased towards CpG rich regions. More 
interestingly, apart from the high preference for CG context in all four cell types, 
we observed that undifferentiated hESCs contained the highest level of non-
CpG methylated context at 20%. In particular, methylated CpA dinucleotides 
(mCpA) emerged as the most prevalent non-CpG methylation with 10% of 
methylcytosine in hESCs in mCpA context compared to PBMCs at 2% (Figure 
8B). In addition, the prevalence of mCpA was also found to be inversely 
correlated with increased differentiation. On the other hand, methylated Cs in 
CpC and CpT dinucleotides (mCpC and mCpT, respectively) were rare and 
displayed minimum differences among the cell types. We further concluded that 
the identity of bases at -1 and +2 positions of methylated Cs had little impact on 
DNA methylation (Figure 8C) with a weak preference (C>T>A>G) at the +2 
position for mCpA as the only observable bias (Figure 8D). Although a global 
decrease in non-CpG (primarily CpA) methylation level was observed with 
differentiation, we found that 93% of the CpA methylation profile was 
conserved among the three differentiated cell types (hESC-Fibro, Fibro and 
PBMCs), this suggest that the presence of CpA methylation was non-random. 
Although hESCs had more CpA methylation compared to other differentiated 
cell types, the same mCpA sites in hESC profile were also present in the other 
cell types.  
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Figure 8. Global DNA methylation distribution during human cell differentiation. 
(A) Distribution of DNA methylation across 4 cell types showed global reduction in 
DNA methylation is inversely correlated with differentiation. (B) The percentage of 
DNA methylation distribution at +1 bp position from methylcytosine, (C) -1 bp from 
methylcytosine, (D) +1 bp from CpA dinucleotides and (F) +1 bp from CpG 
dinucleotides. Note: Diagram was adapted from (Laurent et al. 2010)  
 
With the findings of high non-CpG methylation in hESCs, we were 
interested to determine which DNMTs may be involved in regulating this 
asymmetric methylation. The asymmetric nature of mCpA sites seems to 
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preclude that re-establishment of their methylation during replication may be 
possible through non-specific DNMT3 activity (Ramsahoye et al. 2000). 
Integration of our gene expression analysis, we observed hESCs contained the 
highest expression levels of DNMT3A and in particular DNMT3B (Figure 9A). 
To ensure the observed mCpA activity was not a result from nearby mCpG 
activity, we determined the density of mCpG surrounding mCpAs. The results 
showed that, although the density of CpGs was generally higher surrounding 
CpAs, the density of mCpG surrounding mCpA was no different from the 
density of mCpG found in any random selected CpA site. In addition, we 
validated the mCpA and mCpG using bisulfite PCR and Sanger sequencing at 
Chr11:1181496-1181663 (Figure 9B). Taken together, we confirmed that the 
presence of mCpA was neither random events nor non-specific methylation 
from nearby CpG methylation and the data suggested that the non-CpG 
methylation regulation may be linked to DNMT3B activity. However, the actual 




Figure 9. CpA methylation distribution and the associated DNMTs. 
(A) Gene expression profile of DNMT 1, 3A, 3B and 3L in the three cell types 
performed in 5 replicates together with expression levels from 13 different adult tissues 
and 24 hESC lines. Among the cell types tested, hESCs had the highest levels of 
DNMT3B expression at 1000X higher than the other tissues followed by DNMT3A 
which had slightly elevated expressions in hESC. (B) Bisulfite PCR and sequencing 
validation of mCpA and mCpG at Chr11:1181496-1181663. Independent clones of the 
PCR product were sequenced, mCpG and mCpA were marked by closed circles in blue 
and red, respectively. The opened circles in blue and red represent the unmethylated 




Genomic features associated with DNA methylation.   
 
In the past, the study on DNA methylation had largely focused on gene 
promoter regions mainly due to two reasons; (1) gene promoters were viewed as one 
of the most functionally important genomic feature and (2) technical biased towards 
CpGs rich regions and limited in scale. Thus, it remains unclear how DNA methylation 
is associated with other genomic features and what is the effect of DNA methylation 
together with the interactions of other genomic elements in regulating gene 
transcription? To address these questions, we generated a methylation profile for all 3 
cell types across each chromosome to examine the distribution patterns. Using a 100 
Kb sliding window, the average methylcytosine intensities of total mC, mCpG and 
mCpA were calculated separately across the genome. Overall, we observed the 
baseline level of constitutive methylation to vary among chromosomes. In 
particular, chromosomes 16, 19, and 22 had higher DNA methylation levels 
(Figure 10A), which is correlated to the higher gene density on these 
chromosomes. We further examined the CpG methylation levels along the 
length of each chromosome, where we found uniform baseline level of 
methylation with the exception of sporadic hypomethylated regions (Figure 
10B). Using standard deviations (SD) ±3, we identified 286 hypomethylated 
regions in hESCs which were primarily located in clusters associated with 
promoters and CGIs. Out of which, the HOX A, C, B and D loci had the most 
hypomethylation. The HOX clusters in all four cell types recorded a progressive 
increase in methylation with differentiation (Figure 10C-F).  In hES-Fibro, 103 
out of the 286 hypomethylated regions had higher methylation levels than 
hESCs (SD > 5), while only 71 of the 286 hESC-associated hypomethylated 
regions remained hypomethylated in hESC-Fibro cells. 
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Figure 10. Global distribution of CpG methylation in hESCs during 
differentiation. 
(A) Chromosomal distribution of mCpGs with higher DNA methylation levels at Chr 
16, 19 and 22, marked in red pentagon. (B) Example of chromosomal mCpG at Chr 7 
showed uniform distribution with random regions of hypomethylation clusters such as 
HOXA gene clusters. (C-F) Representative examples of hypomethylated clusters of 
HOX genes with progressive gained in DNA methylation during hESC differentiation 
(C) HOXA, (D) HOXB, (E) HOXC and (F) HOXD. The percentage mCpG tracks for 
hESC, hESC- Fibro, Fibro and PBMC were represented in red, blue, green and yellow, 




Impact of DNA methylation on gene transcription regulation 
 
The relationship between gene promoter and DNA methylation had been 
widely studied with hypermethylation of gene promoters associated with gene 
silencing (Herman and Baylin 2003). However, the relationship of DNA 
methylation to gene transcription at other genomic regions including gene 
bodies, intergenic and transcription terminal sites remains unclear. To 
understand the overall function of DNA methylation during gene transcription 
we mapped the DNA methylation data for each gene that was extracted from 
the Refseq database to a "gene model”. The gene model was defined to contain 
annotated genomic features in the neighborhood of transcribed genes, including 
promoters/transcription start sites (TSS), gene body, transcription termination 
sites (TTS) and intergenic regions. Here, the promoter region is defined as 
region between -10 Kb to +1 Kb from the centre of TSS, TTS region between -
1 Kb to +10 Kb of the TTS, gene body region between +1 Kb from the TSS to 
-1 Kb from the TTS, while intergenic regions were considered as regions not 
within any of the above 3 categories. We first calculated the density of DNA 
methylation in each region and expressed the values in a ratio of methylcytosine 
over total covered Cs. After data normalization of the profiles for all 17,578 
RefSeq genes, a clear DNA methylation pattern was unveiled for all cell types 
investigated (Figure 11A). We observed high methylation throughout most 
promoter regions followed by a sharp dip approximately 1 Kb upstream from 
the TSS reaching the lowest methylation levels at the immediate upstream of 
the TSS. The methylation levels then gradually increased over the initial 
transcribed region and remained high along the intragenic region. Upon 
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reaching the TTS, a small but sharp step down in methylation levels was 
observed where it was further maintained into the intergenic regions.   
 
We further examined the promoter regions by categorizing the genes 
into those CGIs associated promoters (CGI promoters) or non-CGIs associated 
promoters (non- CGI promoters). Next, mCpGs and mCpAs levels were plotted 
separately against the genes (Figure 11B). We observed high similarity between 
the CpG traces and total C traces, except for the TSS regions in genes with non-
CGI promoters. Although, a small peak in mCpGs levels was located 1.5 to 5 
Kb upstream of the non-CGI promoters just before the methylation levels 
decreased at the TSS in all cell lines, the intensity of the peak was not positively 
correlated with transcription. On the other hand, while the mCpAs traces were 
not as distinct as the mCpGs, a clear reduction in methylation at the TSS and a 
step down at the TTS can be observed. Our result showed strong inverse 
correlation in all cell types between CpG density and overall methylation level 
around the promoter regions which was in agreement to earlier reports on 
chromosome 21 (Zhang et al. 2009). For example, our data showed TSS of CGI 
promoters had extreme low levels of CpG methylation (~1.2-2% in hESCs), 
while non-CGI promoters had markedly higher levels of CpG methylation (35-
40% in hESCs) (Figure 11B). In addition, the CGI promoters were associated 
with constitutively expressed genes, while non-CGI promoters were associated 
with developmentally regulated genes. This pattern suggested that the elevated 
levels of DNA methylation at the TSS of non-CGI promoters may make these 
genes more susceptible to regulation by DNA methylation. Among the four cell 
types, hESCs showed the most difference in methylation of CpG and non-CGI 
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promoters. This may suggest that hESCs could be more poised to change the 
activation state of developmentally-regulated genes. 
 
Figure 11. DNA methylation effects on regulation of gene transcription. 
(A) DNA methylation distribution profile along the gene promoter, intragenic regions, 
transcription termination site and intergenic regions in all four cell types. (B) Total 
mCpG and mCpA levels distribution along the gene model in hESCs in genes separated 
into those with promoter CpG islands or without promoter CpG islands. Note: Diagram 
was adapted from (Laurent et al. 2010).  
 
Subsequently, we further explored the relationship between DNA 
methylation and gene expression, by incorporating genome-wide gene 
expression data from three biological replicates of the same hESC, hESC-Fibro, 
and Fibro cell lines, generated on Human WG-6 Gene Expression BeadChip 
(Illumina, Inc.). The 25,159 unique genes were divided into 5 categories ranked 
accordingly to their expression level in decreasing order. We next calculated the 
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average DNA methylation values for each category and mapped the DNA 
methylation values onto the gene model. We found that TSS was strongly anti- 
correlated with gene expression, while methylation levels in the gene body and 
TTS regions were positively correlated with gene expression (Figure 12). For 
example, in hESCs, ±1 Kb of the top 20% most highly expressed genes TSS, 
the DNA methylation was only 0.42%. In contrast, ±1 Kb of the 20% least 
expressed genes TSS had 4.8 % methylation. Correlation coefficient between 
methylation and expression levels at gene bodies and TTS was not calculated 
because the expression array only measures expression level at gene promoters 
so no expression ratios are available at other regions of the gene for coefficient 
correlation calculation. Nevertheless, the results further highlighted the 
involvement of DNA methylation in gene expression regulation.  
 
Figure 12. DNA methylation correlation with gene expression. 
The percentage of DNA methylation in hESCs was plotted along gene model divided 
into four sections (promoter, intragenic, intergenic and TTS) according to the most 
expressed hESCs genes to the least expressed. Strong anti-correlation was observed 
between DNA methylation and gene expression at ±1 Kb of TSS. Note: Diagram was 
adapted from (Laurent et al. 2010).  
 
DNA methylation involvement in regulation of alternative splicing 
 
To further characterize the impact of DNA methylation at various 
genomic features, methylation profiles surrounding the introns, exons, and 
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across splice junctions were investigated. Interestingly, we observed that exons 
were highly methylated at 10.5% in hESCs compared to introns, which were 
methylated at rates close to the genomic average. Next, we observed a change 
in methylation across the splice junctions on both the sense and antisense strands 
at both ends of the intron. Through the analysis, a sharp spike in DNA 
methylation was observed at the 5’ splice site followed by a sharp dip at the 3’ 
splice site of the intron-exon boundary (Figure 13). We suspected that the sharp 
change in methylation level could be likely influenced by the donor/acceptor 
sequence context surrounding the splice junctions. Subsequent analysis showed 
a downward gradient across exons from 5' to 3', in contrast to an upward 
gradient of DNA methylation traveling from 5' to 3' across introns. Although, 
this was a first report of DNA methylation spikes on splice junction, recent 
reports showed that the intron-exon boundaries were marked by gradients in 
chromatin features, including nucleosomes (Schwartz et al. 2009) and the 
H3K36me3 histone mark (Kolasinska-Zwierz et al. 2009).  Hence, our data 
together with existing reports from other groups suggested that coupling of 
transcription and splicing may be regulated by DNA methylation and other 
epigenetic marks.  
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Figure 13. DNA methylation involvement in regulation of alternative splice 
junctions. 
DNA methylation in both sense and anti-sense strand in the three cell types were 
calculated at regions 100 bp upstream and downstream of the donor and acceptor sites. 
A sharp peak was observed at the 5’ donor site in all samples followed by a sharp dip 
in methylation during the transition at the 3’ acceptor site. Note: Diagram was adapted 




DNA methylation correlation with histone modification 
 
Histone modifications are another major epigenetic modification tightly 
intertwined with DNA methylation and is highly involved in transcriptional 
regulation (Meissner et al. 2008). In mouse ES cells, developmentally regulated 
genes were reported to be highly enriched for bivalent marks containing both 
H3K4me3 and H3K27me3, whereas housekeeping genes had univalent marks 
of H3K4me3 (Bernstein et al. 2006). Hence, we were interested to investigate 
the relationship between DNA methylation and chromatin state particularly at 
the bivalent regions in hESCs. We extracted public ChIP-seq datasets of 
H3K4me3 and H3K27me3 generated from the same hESCs cell line (H9 cell 
line) used in our study for comparison (Mikkelsen et al. 2007). Using a 
threshold cutoff of false discovery rate (FDR <0.01), we identified 15,517 
H3K4me3 sites and 6,560 H3K27me3 sites. In total, 11,630 regions were found 
to contain only H3K4me3 marks while 3,887 regions were detected as bivalent 
regions, with another 3,094 regions contained only H3K27me3 mark. In our 
study, we observed strong anti-correlation between DNA methylation located 
within regions with H3K4me3 alone as well as regions having the bivalent 
marks. However, no strong correlation was observed between DNA methylation 
and the inactive H3K27me3 (Figure 14).  
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Figure 14. DNA methylation anti-correlates with active H3K4me3 histone 
modification mark. 
The percentage of DNA methylation in hESCs was plotted surrounding ± 5 Kb 
regions from the center of H3K4me3 and H3K27me3 marks. We noted strong anti-
correlation between DNA methylation and H3K4me3 surrounding ±1 Kb from the 
center of the histone marks. However, no positive correlation was observed between 
the repressive H3K27me3 mark and DNA methylation. Interestingly, strong anti-
correlation was observed between DNA methylation and regions of bivalent marks 
(contain both H3K4me3 and H3K27me3 marks). Note: Diagram was adapted from 
(Laurent et al. 2010). 
 
Differentially methylated regions involved in differentiation  
 
To gain insights on the impact of DNA methylation on cellular 
differentiation, we performed pairwise comparative analysis of the three 
methylomes and identified differentially methylated regions (DMRs) between 
hESCs and hESC-Fibro. We examined if the genes associated with the DMRs 
showed cell-type-specific expression. Overall we found high similarity in 
hESCs and hESC-Fibro DNA methylation patterns with correlation coefficient 
at 0.879 (Figure 15A). Despite the high similarity in DNA methylation patterns, 
pairwise comparison between hESCs and hESC-Fibro across the genome in a 
bin size of 2 Kb identified a total of 4,572 non-overlapping DMRs. 3,621 out of 
the non-overlapping regions had reduced methylation, while 951 regions 
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showed increased methylation in hESC relative to hESC-Fibro. The full list of 
DMRs can be found in the supplemental table 4 of (Laurent et al. 2010). 
Although, globally hESCs has higher methylation levels compared to hESC-
Fibro, during the transition from hESC to hESC-Fibro we observed specific 
regions (up to 4 fold more regions) in hESC-Fibro to be hypermethylated with 
>50% of the regions overlapped with gene regions (promoter, gene body or 
TTS). This suggests that during differentiation the cells undergo a restricted 
pattern of gene expressions at specific regions to stably commit the cells to a 
specific cell-lineage. Subsequent analysis on the genes associated with the 
DMRs was found to be involved in pluripotency, development, and imprinting. 
For example, in hESCs compared with hESC-Fibro cells pluripotency marks, 
NANOG, POU5F1/OCT4, KLF4, and SOX2 showed significantly lower TSS 
methylation (Figure 15B), while TCF3 had higher gene body methylation, this 
was consistent with their higher expression and functional importance in hESCs. 
With differentiation from hESC to hESC-Fibro, we saw increased promoter and 
TTS methylation of transcription factors, particularly the homeobox 
transcription factors such as CDX1, IRX1, and ALX1, and increased gene body 
methylation of cell adhesion molecules and genes associated with G-protein 
signaling. Close examination of CDX1 showed that although the promoter 
region was unmethylated the gene was not expressed in hESCs. Further 
investigation of the promoter showed that it is enriched with bivalent marks 
(Figure 15C). Past studies showed that developmental genes in embryonic stem 
cells (ESCs) were enriched with bivalent marks and contained low promoter 
methylation. It was suggested that these genes remained silenced in ESCs by 
H3K27me3 but are poised for activation upon differentiation by losing either 
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H3K4me3 or H3K27me3 to commit to a specific cell lineage (Bernstein et al. 
2006; Mikkelsen et al. 2007). Gene Ontology (GO) annotations for all DMR-
associated genes showed significant enrichments for genes in the developmental 
processes, transcriptional regulation, and cell-cell communication categories. 
The GO annotations can be found from supplemental table 3 of (Laurent et al. 
2010).  
 
Figure 15. Examples of differentially methylated regions in hESCs and hES-Fibro. 
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(A) Scatter plot on the distribution of methylated Cs derived from hESC and hES-
Fibro DMRs. A solid red line marked the mean differences in methylated Cs between 
hES and hES-Fibro. A dashed red line indicates methylated Cs with mean difference 
of SD >5 from the mean DNA methylation differences. Representative examples of 
differentially methylated regions identified in hESCs over hES-Fibro at promoter and 




In this study, we demonstrated that WGB-seq offers great genome wide 
coverage of 5mCs at single-nucleotide resolution. We showed that using this 
approach together with different cell differentiation states, we were able to 
investigate the relationships between DNA methylation and local sequence 
features, gene expression levels, and histone modifications. Furthermore, it 
enabled us to examine the effects of cellular differentiation on DNA methylation 
both globally and locally at specific nucleotides.  
 
Through our analysis, we found that all three cell types had similar DNA 
methylation patterns when we mapped their methylation profiles against 
different genomic features as displayed on a gene model (Figure 11A). Using 
the gene model, higher DNA methylation was observed in the gene body, 
intergenic and distal promoter regions, with decreased methylation levels at the 
TSS followed by a small step down at the TTS. Our data demonstrated that the 
decrease in methylation at the TSS was anti-correlated with gene expression, 
while levels of methylation upstream of TSS and within the gene body were 
correlated with gene expression. Such higher gene bodies methylation were 
previously reported in both Arabidopsis (Cokus et al. 2008; Lister et al. 2008) 
and mammals (Ball et al. 2009). The presence of higher gene body methylation 
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was suggested to interfere with non-productive transcription initiation within 
transcribed regions which may improve the transcription efficiency of actively 
transcribed genes (Ball et al. 2009). Subsequent investigation of the relationship 
between DNA methylation and histone modification revealed a strong anti-
correlation between DNA methylation and H3K4me3 occupancy, a mark of 
active transcription. This further confirmed that DNA methylation is closely 
related to local chromatin conformation (Meissner et al. 2008).  
 
Close examination of DNA methylation at the exons and introns 
revealed distinctly higher methylation levels at the exons over the introns. 
Nevertheless, we suspect that the higher methylation levels at exons may be 
influenced by the higher GC contents of exons compared to the regional introns. 
More interesting, these patterns correlate with nucleosome occupancy and 
histone modifications, H3K36me3, suggesting potential involvement of 
chromatin structure in splicing (Kolasinska-Zwierz et al. 2009; Schwartz et al. 
2009). In addition, distinct patterns of methylation across exon-intron 
boundaries were also observed in our data, which may provide new insights on 
transcript splicing regulation by methylation. In this study, we observed distinct 
methylation profile in both the sense and anti-sense DNA strands consisting of 
a spike in methylation followed by a sharp plunge in methylation at the 5’exon-
intron boundary. A gradual rise in methylation across the following intron was 
observed and accompanied by a downward deflection and sharp transition to a 
higher methylation level at the 3' intron-exon boundary. The presence of the 
sharp transition may serve as a signal for regulation of mRNA splicing. 
Together with results from previous studies, this positively suggest that 
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chromatin modification and DNA methylation may work in concert to regulate 
the generation of specific splice variants (Sims et al. 2007; Loomis et al. 2009). 
Hence, we suggest that differential methylation patterns may modulate the 
chromatin conformation to facilitate the recognition of exon-intron boundaries, 
and the binding of specific histones may in turn affect DNA methylation. 
However, the exact roles of chromatin and methylation in differential splicing 
will have to be determined by experimental studies.  
 
In addition, the unbiased nature of WGB-seq enables us to evaluate non-
CpG methylation which was previously impossible by techniques biased against 
CpG methylation such as RRBS and Methyl-seq. We found that CpA 
methylation is the most predominant non-CpG methylation in hESCs and it is 
inversely correlated with differentiation. We further demonstrated that CpA 
methylation profile was similar to CpG methylation in transcribed regions 
where both CGI and non-CGI promoters were hypomethylated but with 
consistent gene body methylation. Although the mechanisms involved in 
regulating non-CpG methylation is unclear. Past studies had demonstrated that 
DNMT3A (in mouse) or DNMT2 (in Drosophila) may be involved in 
establishing non-CpG methylation (Lyko et al. 2000; Ramsahoye et al. 2000). 
Although in our studies, we observed expression level of DNMT3B having the 
best correlation with non-CpG methylation further experiments are required to 




Detailed analysis of CpG methylation profiles identified regions of 
hypomethylated CpGs in the hESCs to be preferentially located in 
promoter/CGIs areas, which progressively disappeared with differentiation. For 
example, the HOX gene clusters with hypomethylated regions significantly had 
increased DNA methylation with differentiation from hESC to hESC-Fibro. 
Finally, we were able to screen for DMRs during differentiation by comparing 
methylated or demethylated regions between hESCs and hESC-Fibro. We found 
that these DMRs were mostly located in promoter, gene body and TTS regions. 
Despite in global reduction of DNA methylation during differentiation, we 
found > 80% of DMRs had increased methylation with differentiation. Through 
the DMRs analysis we were able to identify key pluripotency and 
differentiation-associated genes. 
 
In conclusion, our results highlighted the advantages of unbiased whole-
genome approach to characterize genome wide methylation maps. By 
integrating, genome-wide gene expression and chromatin binding studies, we 
can further develop a dynamic model for understanding gene regulation in 
complex processes such as cellular differentiation. More importantly, the results 
from our study open doors for future investigation including exploration of the 
functional significance of non-CpG methylation in the establishment and 
maintenance of the pluripotent state. As well as the potential of DNA 
methylation regulation in cell type specific splicing. Thus, comprehensive DNA 
methylation maps together with other systems-level data may guide us to 
understanding the mechanisms involved in specific pathways of differentiation 
during human development. 
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Materials and methods 
Note: All experiments, data analysis and data interpretation was performed by me 
unless otherwise stated at the bottom of each section of the materials and methods.  
Cell cultures and genomic DNA extraction 
 
Human Embryonic Stem cells (hESCs) line (WA09, H9) obtained from 
(WiCell) was cultured in feeder-free conditions using matrigel (Becton 
Dickson) in StemProTM medium (Life Technologies) (Thomson et al. 1998). 
hES-Fibro and Fibro were obtained from (GlobalStem, Inc) and cultured in 
DMEM supplemented with 10%FBS (Gonzalez et al. 2008). Genomic DNA 
(gDNA) was extracted and purified using DNeasy Blood & Tissue Kit 
according to manufacturer’s instruction (Qiagen). Note: hESCs, hES-Fibro and 
Fibro cells genomic DNA was provided by Dr Louise Laurent, The Scripps Institute, 
USA. 
 
Whole genome bisulfite sequencing library construction  
 
WGB-seq libraries were constructed from hES, hES-Fibro and Fibro as 
described in (Laurent et al. 2010). Briefly, 5 µg of purified gDNA from hES, 
hES-Fibro and Fibro cells were randomly sheared into fragments between 300 
to 800 bp at 45psi for 4min using nebulization (Illumina). An aliquot of the 
sheared DNA was run on a DNA1000 Chip (Agilent Technologies) to check for 
the size distribution. The DNA was end polished by T4 DNA polymerase and 
T4 PNK (Illumina). The DNA was 3’ A-tailed using Klenow exo (3’ to 5’ exo 
minus) enzyme (Illumina) to attach an ‘A’ base to the 3’ end which is required 
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to ligate the T-overhang methylated PE adapter. Next, methylated PE 
sequencing adapter (Illumina) was ligated on both ends of the DNA at a final 
adapter concentration of 0.2 ng/µl. All Cs in the adapters were pre-methylated 
to prevent C-T conversion during bisulfite treatment. Next, three independent 
bisulfite reactions were setup, each with a starting amount of 1µg adapters- 
ligated DNA using EpiTect Bisulfite Kit (Qiagen) according to the 
manufacturer’s instructions with slight modification. The samples undergo 
bisulfite conversion in a MJ thermocyler (GMI) using the following program: 
(1) 2 cycles of 99°C for 5 min; (2) 60°C for 25 min; (3) 99°C for 5 min; (4) 
60°C for 85 min; (5) 99 °C for 5 min; (6) 60°C for 175 min; and (7) 20 °C 
forever. The bisulfite converted DNA was purified, and pooled for PCR 
amplification using a final concentration of 0.1 U/µl Pfu TurboCx Hotstart DNA 
polymerase (Stratagene). The PCR program used for amplifying the bisulfite 
converted DNA was: (1) 95C for 5 min; (2) 8 cycles of 95C for 30 s; (3) 65C 
for 20 s; (4) 72C for 30 s; and (5) final extension 72C for 7 min followed by 
4C forever. The amplified DNA was run in a 2% agarose gel, a smear fraction 
between 250 to 350 bp was excised. The DNA samples were sequenced using 
Illumina PE sequencing kit at 2X 76 bp according to manufacturer’s 
recommendations (Illumina).  
 
HumanMethylation27 BeadChip array 
 
DNA microarray based DNA methylation analysis was performed on 
two biological replicates for hESC, hESC-Fibro, and Fibro cells using 
HumanMethylation27 BeadChip (Illumina). 500 ng of gDNA from each cell 
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lines was bisulfite converted using EZ DNA Methylation Kit according to 
manufacturer’s instructions (Zymo Research). The treated DNA was hybridized 
onto a HumanMethylation27 BeadChip and scanned using BeadArray Reader 
(Illumina). DNA methylation ratio was expressed in a β-value, where β= 
methylated Cs/ methylated and unmethylated Cs. The β-value for each sample 
was normalized using data from fully methylated (generated by treating gDNA 
with SssI DNA methyltransferase), fully unmethylated (generated by whole-
genome amplification of gDNA), and partially methylated (generated by mixing 
equal amounts of fully methylated and fully methylated gDNA) control DNA 
samples run in triplicate. Note: The HumanMethylation27 BeadChip array data was 
provided by Dr Louise Laurent, The Scripps Institute, USA. 
 
Gene expression microarrays 
 
Gene expression analysis was performed on three biological replicates 
for the hESC, hESC-Fibro, and Fibro cells using Human WG-6 version 3 Gene 
Expression BeadChip (Illumina) containing 48,000 probes. Total RNA was 
purified from each cell lines using MirVana RNA extraction kit (Ambion). 100 
ng input total RNA was amplified and labeled using the TotalPrep kit (Ambion). 
The labeled product was hybridized onto the array and scanned on a BeadArray 
Reader (Illumina) according to the manufacturer’s instructions. The data were 
quintiles normalized, and unexpressed probes (detection p-value >0.01) were 
removed. Note: The gene expression microarray assay was provided by Dr Louise 
Laurent, The Scripps Institute, USA. 
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Bisulfite genomic PCR (BSP), cloning and Sanger sequencing  
 
To quantify the methylation levels of specific target regions, BSP and 
sequencing was performed. DNA extracted from hES, hES-Fibro and Fibro 
were bisulfite treated and PCR amplified. PCR primers (1st base) were designed 
to contain no CpG sites within 500 bp of the gene promoters using MethPrimer 
(http://www.urogene.org/methprimer/index1.html) (Li and Dahiya 2002). We used 
the RepeatMasker track (Meyer et al. 2012) in UCSC Genome Browser to avoid 
having primers covering repeat regions (Kent et al. 2002). 10 ng of bisulfite 
treated DNA were PCR amplified using a final concentration of 0.1 U/µl Pfu 
TurboCx Hotstart DNA polymerase (Stratagene). The BSP program used was 
(1) 95C for 3 min; (2) 35 cycles of 95C for 30 s; (3) 56C for 30 s; (4) 72C 
for 30 s; and (5) final extension 72C for 1 min followed by 4C forever. The 
amplified DNA was run in 1.5% agarose gel and the PCR bands were excised 
for cloning. The amplified DNA was cloned into a TOPO Zero Blunt vector 
(Life Technologies) and transformed into TOP10 electro competent cells (Life 
Technologies). The cells were plated onto LB agar plate with Kanamycin 
antibiotics (50mg/ml) (Sigma Aldrich) followed by overnight incubation (20 
hrs) at 37C. 20 clones were randomly picked from the LB agar plate to perform 
colony PCR using 0.1 U/µl Taq DNA polymerase (Qiagen). The colony PCR 
program was; (1) 94C for 3 min; (2) 25 cycles of 94C for 30 s; (3) 60C for 
30 s; (4) 72C for 1 min; and (5) final extension 72C for 10 min followed by 
4C forever. The resulting PCR products were purified using Qiaquick PCR 




Bisulfite genomic PCR (BSP) and Sanger sequencing analysis 
 
To quantify the methylation levels of specific target regions, the DNA 
sequences generated from BSP were analyzed using public available software 
tool, BiQ Analzyer v2.00 (http://biq-analyzer.bioinf.mpi-inf.mpg.de/) (Bock et al. 
2005). In this software, the human reference sequences of the PCR region 
extracted from UCSC Genome Browser, hg18, were automatically converted 
into a 3-base sequence. In which, the software replaced all non-CpG ‘Cs’ to Ts. 
Next, DNA sequences from the individual PCR clones were aligned to the 
converted reference sequences using Clustal W multiple alignment (Thompson 
et al. 1994). Sequences with <80% sequence identity against the reference 
sequence were filtered. Next, the bisulfite conversion rate was calculated by 
taking the ratio of unmethylated non-CpG ‘Cs’ converted to Ts over the total 
number of methylated and unmethylated non-CpG ‘Cs’ in the PCR amplified 
region. Sequences with <90% bisulfite conversion rate were removed from 
subsequent analysis to ensure data accuracy. Only clones which passed the 
above filtering criteria were used for the downstream analysis. The final 
methylation levels of an individual CpGs sites within the PCR region were 
calculated by taking the ratio of number of clones called methylated CpGs over 
total number of sequenced clones. The results were then visualized in a 
‘lollipop’ diagram where each circle represents a CpG site with methylated 
CpGs in black, unmethylated CpGs in white.    
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WGB-seq alignment and 5mC identification  
 
WGB-seq reads generated from Illumina Genome Analyzer were first 
processed by CASAVA ver. 1.7 for base calling and quality score filtering. The 
passed filter (PF) reads were aligned to human reference genome, hg18, in a 
four step process. (1) In silico Cs to Ts replacement of all non-CpG ‘Cs’ in both 
sense strand of sequence reads and reference genome. (2) Complementary in 
silico replacement of Gs to As of the non-CpG ‘Cs’ in both antisense strand of 
sequence reads and reference genome. (3) Alignment of the converted 
sequenced reads to the respective converted genome using Short 
Oligonucleotide Alignment Program 2 (SOAP2) (Li et al. 2008; Li et al. 2009) 
with up to 2 bp mismatches. Reads with multiple alignment locations as well as 
reads that contained the same start and end alignment location were discarded. 
The aligned reads were reverted to their original form and compared against the 
unconverted reference genome. Cs which remained unchanged before and after 
bisulfite treatment were classified as methylated Cs while Cs that appeared as 
Ts after bisulfite conversion were classified as unmethylated Cs. (4) Rescue: 
Sequencing errors often accumulate at the 3’-end of the reads which prevented 
some reads from being aligned to the reference. To counter this issue, SOAP2 
will trim the bases at the 3’-end and attempt for realignment. The process will 
repeat itself until the read gets aligned or when the remaining read is too short 
for accurate mapping (under 25 bp). The rescue reads were subsequently 
reprocessed by the main pipeline to distinguish the methylated Cs. Next, we 
calculated the methylation status of each C in the genome accessed by the 
sequence reads by taking the number of reads called methylated Cs over the 
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total number of reads covering the position. To ensure data accuracy, Cs with 
less than 3 reads coverage was removed from all downstream analysis. Since 
populations of cells were accessed from each cell lines, the methylation status 
at a specific site can vary; hence we expressed the methylation status in a 
continuous β-value between 0 to 100%. Cs with β-value 80% <β < 100% were 
labeled methylated (M), 60% <β < 80%, intermediate between partially 
methylated and methylated (M_P), 40% < β < 60% partially methylated (P), 
20% < β < 40% intermediate between unmethylated and partially methylated 
(U_P), and 0% < β <20% unmethylated (U). The WGB-seq data can be 
downloaded from NCBI GEO database under the ID: GSE19418. The library 
IDs for the individual samples are GHE002 (hESCs), GHF002 (hESC-Fibro) 
and GHN002 (Fibro). Note. WGB-seq alignment was performed by Dr Zhou 
Guangyu and Dr Wu Honglong, Beijing Genomics Institute, China. The identification 
of 5mC was performed by Dr Li Guoliang, Genome Institute of Singapore, Singapore.      
 
Generating methylation profile along gene model  
 
To generate the methylation profile along the gene transcripts, we first 
defined a gene model by classifying the gene into 4 categories; promoter (-10 
Kb to +1 Kb from the TSS), intragenic region (+1 Kb to -10 Kb from TTS), 3’ 
region (-10 Kb to +1 Kb from TTS) and intergenic regions define as all other 
regions not within the above categories. To ensure data accuracy, only gene 
transcripts ≥2 Kb in length were used. Based on the above selection criteria 
17,578 out of 19,296 Refseq genes were used for this analysis. The methylation 
levels were calculated for each transcript along the respective gene region as 
defined in the gene model. DNA methylation levels within the promoter and 3’ 
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region were calculated using a bin size of 100 bp (average DNA methylation 
levels were calculated by taking the number of methylated Cs (M ≥60%) over 
total covered Cs at every 100 bp) while methylation levels in intragenic and 
intergenic regions were calculated using bin size of 1000 bp (similarly, average 
DNA methylation levels were calculated at every 1000 bp). The methylation 
levels from each transcript were overlapped and average to obtain the final 
methylation profile for each cell line along the gene model. Note. The script to 
identify the gene model was written by Dr Li Guoliang, Genome Institute of Singapore, 
Singapore.  
 
Identification of Differentially Methylated Regions (DMRs) 
 
To identify differentially methylated regions (DMRs) related to cell 
differentiation, pairwise comparison was performed between hESCs and hESC-
Fibro cells using a 2 Kb sliding window. In each window, the numbers of 
methylated Cs (M ≥60%) were calculated. Only windows with ≥5 methylated 
Cs were used for subsequent analysis. In total 1.8 million windows were 
identified, we calculated the difference in the number of methylated Cs between 
the cells. The differences in methylated Cs between the cells were plotted in a 
histogram followed by the calculation of the mean and standard deviation. 
Regions with differences of standard deviation (SD) >5 in global methylation 
level from the mean distribution (p-value <10-6 for a normal distribution) were 
identified as DMRs. The identified DMRs were subdivided into 
hypermethylated DMRs (SD ≥5) and hypomethylated DMRs (SD ≤ -5). To 
determine the genomic features associated with each DMR, we annotated each 
DMR by mapping the center of the DMR to the nearest genomic features of the 
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proximal genes. TSS DMRs were centered [-10 Kb, +1 Kb] to a TSS, TTS 
DMRs were centered [-1 Kb, +10 Kb] to a TTS, intragenic DMRs were centered 
in the region > [+1 Kb] to a TSS and < [-1 Kb] to the corresponding TTS, while 
all other DMRs were annotated as intergenic.  
 
Gene Ontology (GO) analysis was performed on the DMRs associated 
genes using public available tool Panther Classification System 
(http://www.pantherdb.org/) (Thomas et al. 2003) with Bonferroni correction and 
a p-value threshold of 0.05 to determine what pathway, biological processes and 
molecular functions were enriched by the DMR associated genes. Note. The 
script to identify DMRs was written by Dr Li Guoliang, Genome Institute of Singapore, 
Singapore.  
 
H3K4me3 and H3K27me3 ChIP-seq analysis 
 
H3K4me3 and H3K27me3 ChIP-seq data constructed from H9 hESCs 
were downloaded from public databases GSM327662 and GSM327663, 
respectively (Ku et al. 2008). The raw data were reprocessed and a threshold of 
false discovery rate (FDR ≤ 0.001) was applied to obtain high confidence 
H3K4me3 and H3K27me3 ChIP-seq binding sites. In total, 15,517 H3K4me3 
sites and 6,560 H3K27me3 sites were identified. To investigate the relationship 
between histone modifications and DNA methylation, the average DNA 
methylation levels were calculated in bin size (100 bp), ± 500 bp from the center 
of each ChIP-seq peaks. The average DNA methylation levels obtained were 
plotted against the distance upstream and downstream from the center of the 
histone peaks. Note: Correlation analysis between histone modification and DNA 
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Chapter Three: Global reduction in DNA methylation accompanied by 





The accumulation of epigenetic alterations and genetic mutations had 
been known to be the attributes of cancer development. Colorectal cancer (CRC) 
is one of the major cancer malignancies in the world which accounts for over 
9% of all cancer incidences and affects both men and women (Ferlay et al. 
2010). Often patients with CRC have reduced survival rates and prognosis upon 
the development of metastatic CRC. The development of metastasis from tumor 
cells is a complex process that involves epithelial-mesenchymal transition 
(EMT), cell migration as well as local invasion. This allows cancer cells to 
invade the underlying colorectal epithelium for migration into other organs 
(Joyce et al. 2006; Ganepola et al. 2010). Despite metastatic CRC having a 
worse prognosis than primary tumor, it was reported that genetic mutations in 
metastatic cancers were also present in their matched primary tumor (Jones et 
al. 2008), suggesting epigenetic changes as one of the major contributor in 
directing the local transition from primary tumor to metastasis. In particular, 
tumor suppressor function genes such as WIF1, APC and RASSF2A were 
frequently silenced in CRC patients by DNA hypermethylation (Arnold et al. 
2004; Taniguchi et al. 2005; Lee et al. 2009).  
 
Based on the success of the genome wide hESCs methylome profiling, 
the same technique WGB-seq was applied to access the DNA methylation 
alterations during cancer progression using CRC as a study model. Here, 
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comprehensive comparative analysis was performed between normal, tumor 
and metastasis CRC which enables us to locate key differential methylation 
regions that may be involved in the transition process from tumor to metastasis. 
In addition, identify the important genes that are potentially associated with 
tumor development and progression which might serve as future biomarkers for 
diagnosis.   
 
Results 
Library construction and methylation status classification 
To characterize the genome wide methylation patterns in different stages 
of CRC, WGB-seq was performed on a set of normal colon mucosa (N), primary 
colon tumor (T) and colon with liver metastasis (M) tissues derived from one 
patient. As a reference, WGB-seq libraries were also constructed on a wild type 
(WT) CRC cell line, HCT116 and a double knockout (DKO) HCT116 with two 
genetically disrupted genes DNMT1 and 3B. It was showed that upon genetic 
disruption, the DKO cells recorded up to 95% of genome DNA methylation 
removed (Rhee et al. 2002). Hence, the cells were chosen as a standard of 
reference to represent a de-methylated genome state, where we can use the WT 
and DKO methylation maps to differentiate gene expression regulated by DNA 
methylation. In total, more than 860 million reads of readlength up to 50 bp for 
each WGB-seq libraries were generated. The sequencing reads were aligned to 
the human reference genome, hg19 using BatMeth with up to 2 bp mismatches 
(See Chapter Three: Materials and methods for details of BatMeth mapping). 
By using BatMeth alignment program, we achieved a mapping rate of above 
75% (mapping rate refers to the number of reads mapped to the reference 
genome) and obtained an average of 40 billion uniquely mapped reads per 
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sample to give a coverage depth of ~14X. The estimated bisulfite conversion 
rate of each WGB-seq library was >96% (Table 4) with the exception of WT 
HCT116 at 90.7%. Although all the samples were subjected to 2X bisulfite 
conversion, the samples on the whole had lower conversion rate which may be 
due to different batches of the bisulfite reagents. Overall, our sequencing data 
covers >80% of total Cs in the genome and >75% of CpGs with at least 1 read 
coverage (Figure 16A and 16B). Given that we examined a population of cells, 
we thus expressed the methylation status of each detected Cs in a ratio from 0 
to 100%. The methylation ratio was calculated based on the number of reads 
detected as methyl Cs over the number of reads detected as Cs or Ts. 
Subsequently, each methyl Cs was categorized into one of the following: 
Methylated (M >60%), partially methylated (20% <, P, ≥ 60%), and lowly 
methylated (L < 20%). We further validated our WGB-seq data against an 
independent platform Illumina Infinium HumanMethylation27K array assay 
with the same samples used for sequencing. High correlation in methylation 
calling status was observed between both platforms for normal colon tissue (r = 
0.91), while tumor and metastasis tissue have lower correlation levels (r = 0.65 
and 0.68, respectively) (Figure 16C and Table 5). Together, the methylome data 





Library ID GHH004 GHH005 WHC005 WHC003 WHC004
Description DNMT1 & 3B DKO HCT116 cell line 
Wild type  
HCT116 cell line Normal colon mucosa Primary colon tumor 
Colon with liver 
metastasis 
# of sequencing runs 6 5 3 3 3 
Type of sequencing 2 X 51 bp 2 X 51 bp 2 X 51 bp 2 X 51 bp 2 X 51 bp 
           









Mapped reads 1,008,361,635 50.4 702,203,059 35.1 793,026,400 39.7 823,968,158 41.2 1,008,090,227 50.4 
Mapping rate 75.6% 77.4% 79.4% 81.3% 81.0% 
Non-redundant 
mapped reads 970,605,685 48.5 591,898,793 29.6 758,150,192 37.9 784,559,735 39.2 957,952,051 47.9 
% Redundancy 3.7% 15.7% 4.4% 4.8% 5.0% 
Est. sequencing 
depth 16.1 X 9.9 X 12.6 X 13.1 X 16.0 X 
% Bisulfite 
Conversion rate 95.9% 90.7% 97.0% 96.9% 97.1% 
Total covered bases  
 (≥3 tags) 2.41E+09 2.21E+09 2.53E+09 2.54E+09 2.57E+09 
% genome coverage 
(≥3 tags) 77.8% 71.3% 81.7% 81.9% 83.0% 
# of C covered   
( At least 1 tag) 783,469,403 647,156,912 774,569,800 771,924,727 806,113,919 
% of C covered 66.96% 55.31% 66.20% 65.97% 68.90% 
# of CpGs covered  
 (At least 1 tag) 44,878,433 40,242,852 42,703,266 42,708,938 43,909,110 
% of CpGs covered 79.52% 71.31% 75.67% 75.68% 77.80% 
 
Table 4. WGB-seq libraries sequencing and mapping statistics for normal, tumor, metastasis colon and HCT116 cells. 
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Figure 16. Validation of WGB-seq data coverage and methylation calling strategy. 
The percentage of (A) total Cs and (B) total CpGs coverage in the genome with 3 or 
more reads coverage. (C) Heat map of methylation calling status between methyl27K 
array and WGB-seq for normal, tumor and metastasis colon. Methylated Cs covered by 
both platforms was categorized into the same methylation calling status to determine 
the correlation. High correlation was observed between methylated Cs detected in 
methyl27K array and WGB-seq with red being the most correlated and blue being the 
least correlated.  
Normal  
#CpG by Methyl27K array 27,566 
#CpG by WGB-seq 19,357,492 
#CpG common between 
WGB-seq & Methyl-array 23,847 
#CpG common between WGB-seq 
& Methyl-array (and in same methyl-category) 17,648 
% of CpG with same methyl category  
between WGB-seq & methyl27K array 74.01% 




#CpG by Methyl27K array 27,566 
#CpG by WGB-seq 19,397,390 
#CpG common between 
WGB-seq & Methyl-array 22,848 
#CpG common between WGB-seq  
& Methyl-array (and in same methyl-category) 14,874 
% of CpG with same methyl category between 
WGB-seq & methyl27K array 65.10% 
Pearson correlation ratio 0.65 
  
Metastasis  
#CpG by Methyl27K array 27,566 
#CpG by WGB-seq 20,287,165 
#CpG common between 
WGB-seq & Methyl-array 23,847 
#CpG common between WGB-seq  
& Methyl-array (and in same methyl-category) 14,341 
% of CpG with same methyl category between 
WGB-seq & methyl27K array 60.14% 
Pearson correlation ratio 0.68 
 
Table 5. Comparison of methylated CpGs detected between WGB-seq and 
Methyl27K array. 
 
Next, we performed hierarchical clustering of DNA methylation levels 
between the three cell types using a 1 Kb bin size throughout the genome. 
Through the analysis, the methylation profile of the three cell types are closely 
related in the direction of N>T>M, with metastasis having slightly lower 
Pearson correlation r = 0.89 relative to the normal colon (Figure 17).  
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Figure 17. Hierarchical clustering of DNA methylation levels between normal, 
tumor and metastasis colon. 
DNA methylation levels across the genome were calculated in a bin size of 1 Kb for 
normal, tumor, metastasis, WT and DKO HCT116 cells. Correlation coefficients 
between each pair of cell types were generated and grouped accordingly from the 
highest (in white) to the least correlated (in red). 
 
Global colorectal cancer methylome landscape during tumor progression 
 
To gain insights on the alteration of DNA methylation during cancer 
progression, we first compared the global methylation profile of the three tissues 
by calculating the mean methylation levels across the genome using a fixed 
window size of 5 Kb. Through the analysis, the cancer genome was observed to 
undergo hypomethylation with metastasis cells being the most hypomethylated. 
HCT116 double knockout (DKO) cells with genetically disrupted DNMT1 and 
3B also showed major depletion in total DNA methylation compared to the wild 
type HCT116 (Figure 18A). We further measured the total CpG methylation in 
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all three tissues in which we recorded at least 11% of CpG methylation levels 
reduction from normal colon at 66.90% to 55.79% in metastasis cells, while 
tumor cells only detected a 2% reduction in CpG methylation (Figure 18B). 
Such level of CpG methylation reduction were comparable to previous reports 
of 10% and 20% CpG methylation reduction between normal and cancer tissues 
(Feinberg and Vogelstein 1983; Ehrlich 2002). Compared to the tissue samples, 
HCT116 cell line is highly methylated 75.2%. The higher methylation levels in 
HCT116 may be due to the nature that cell lines contain more homogenous 
cancer cell population while actual tissues are highly heterogeneous. We further 
characterized the methylome profiles against different genomic features 
including CGIs, CGIs-shores, gene regulatory elements and repeat elements 
(Figure 18C-E and 20). Despite the cancer cells having a global CpG 
methylation reduction, the levels of CpG methylation within CGIs was reversed. 
Metastasis cells compared to tumor and normal had higher levels of CGI 
methylation (Figure 18C). In the genome, it was showed that only 7% of the 
CpG dinucleotides are located within CGIs (Rollins et al. 2006) hence, it is not 
surprising that the effect of increased CGIs methylation in cancer cells was not 
reflected in the overall CpG methylation reduction. Similarly, high levels of 
CGIs methylation were observed in WT HCT116 while DKO cells which 
represent a state of demethylation consistently had low CpG methylation in 
CGIs as well as across the entire genome. CGI-shores defined as regions within 
2 Kb upstream and downstream of CGIs was previously described to be highly 
correlated with gene regulation and used to differentiate between benign and 
malignant phenotype (Irizarry et al. 2009; Feber et al. 2011). However, in our 
study only subtle changes in CpG methylation within the CGI-shores from 
79 
normal to tumor and to metastasis (N>T>M) was observed (Figure 18D). We 
subsequently annotated the CpG methylation levels across proximal promoters, 
distal promoters, introns, exons and intergenic regions. Overall, we observed 
minimal change in CpG methylation at the proximal promoter (± 2 Kb from the 
TSS) and exons among the three tissues. Distal promoters (2 to 10 Kb upstream 
of the TSS), introns and intergenic regions showed reduced CpG methylation 
from normal to cancer (Figure 18E).  
 
Figure 18. Global DNA methylation profile during CRC progression. 
(A) Mean DNA methylation was calculated in a 5 Kb window across the genome, and 
cluster from the least to the highest methylation levels using normal colon as a 
reference. (B) Percentage CpG methylation distribution in normal and cancer cells 
showed reduced CpG methylation with increased malignancy. (C) Increased CpG 
methylation was observed in CpG islands from normal to cancer cells. (D) Subtle 
change in DNA methylation levels were observed at CGI-shores that were defined 
within 2 Kb of a CGIs. (E) Percentage CpG methylation distribution in gene features.  
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In our previous study as well as others, non-CpG methylation in 
particular CpA methylation was identified in human ES cells (Lister et al. 2009; 
Laurent et al. 2010). More recently, CpA methylation was also identified in 
adult brain tissues with a sequence preference of CACC (Varley et al. 2013). 
Although the role of CpA methylation is currently unclear, we were interested 
to determine if cancer cells with stem-like properties also contain non-CpG 
methylation. We analyzed the +1 bp position of methyl Cs (CpH, where H= A, 
T, C, G) for any sequence preference. However, negligible change in numbers 
of methylation was detected between normal and cancer colon at mCpA, mCpT 
and mCpC. The total DNA methylation levels in non-CpG dinucleotides context 
in both normal and cancer cells showed an average of 12%, similar to levels 
previously detected in fibroblast cells (~14%) (Figure 19).  
 
Figure 19. Percentage non-CpG methylation in cancer cells. 
We examined the +1 bp position of methyl cytosines across 3 tissues and 3 cell lines 
colon tissues for any sequence context preferences. However, negligible levels of non-
CpG methylation were detected in all tissues and cell lines suggesting that non-CpG 
methylation is not altered in adult colon tissues.   
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Hypomethylation in repeat elements had been associated to cause 
genome instability in cancer (Ehrlich 2002). To identify any specific repeat 
elements involved in causing CRC genomic instability, we accessed the CpG 
methylation profile of the three tissues at 12 repeat elements including LINEs, 
SINEs, MIR and satellite repeats. Globally, increased hypomethylation was 
observed across all the measured repeats except for low complexity repeats 
which showed an increased in DNA methylation during cancer progression. In 
addition, LINE1 and 2 had the most significant difference in hypomethylation 
from normal to metastasis at ~18% (p-value, 1.87E-05) followed by ERV and 
LTR at ~16.7% (p-value 4.45E-05 and 4.48E-05, respectively) (Figure 20). 
Although LINE1 repeat hypomethylation has previously been reported to be 
associated with poor CRC prognosis (Ogino et al. 2008), the relationship 
between hypomethylation at LINE2, LTR and ERV with CRC prognosis and 
genome instability remains to be investigated.  
 
Figure 20. Reduction of CpG methylation in repetitive elements during CRC 
progression. 
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Mean CpG methylation levels were calculated across 12 repeat elements in all 3 tissues. 
LINE1 and LINE2 showed the largest difference between normal and cancer cells with 
the most significant change in CpG methylation.  
 
Identification of large clusters of demethylated regions in metastasis cells  
 
Comparative genome wide analysis of the 3 methylome was performed 
to further characterize the differences in methylation patterns during cancer 
progression. Using a fixed window size of 5 Kb, the mean CpG methylation 
levels were calculated in each window across all 3 cells. A region is defined as 
demethylated with at least 20% mean methylation reduction between normal 
and metastasis. Neighboring regions with the same direction of methylation 
changes of >20% difference were merged to form the final large demethylated 
regions. Using these criteria, 20,186 regions ranging between 5 Kb to 1.5 Mb 
were identified. These regions had an average of 20-40% CpG methylation and 
makes up 32% of the genome (Figure 21A and B). To gain insights to these 
large demethylated clusters and their impact on gene transcription, we annotated 
the regions to the nearest gene features. Here, we found that the demethylated 
clusters were mostly located in regions with gene poor density and non-
overlapping with CGIs (Figure 21C and D). We further integrated our ChIP-seq 
data from different transcription regulators to determine how these 
demethylated regions maybe regulated. These include the active promoter 
marks H3K4me3, RNA Polymerase II (RNA PolII), the enhancer marker 
H3K4me1, insulator CTCF and repressive marker H3K27me3. We checked the 
level of DNA methylation of different transcription regulators within and at the 
boundaries of the demethylated regions. Overall the demethylated regions do 
not show enrichment for H3K4me3, RNA PolII and CTCF peaks (Figure 22). 
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These hypomethylated blocks were mostly located in gene poor density regions, 
thus not surprising to have poor enrichment of the active marks H3K4me3 and 
RNA PolII. Although the demethylated regions were mostly depleted of CTCF 
binding peaks, to our surprise we observed long range CTCF chromatin 
interaction loops overlapping the demethylated regions. Previous studies had 
demonstrated that CTCF binding peaks are involved in long range chromosomal 
interactions to regulate genes that were mega bases apart (Handoko et al. 2011). 
Thus, we were interested to determine if the hypomethylated regions may be 
regulated by long range chromatin interactions. The demethylated regions were 
annotated against our unpublished CTCF long range chromatin interaction 
(ChIA-PET) loops in HCT116 and MCF-7 (breast cancer cell line) by extending 
the boundaries of the demethylated blocks by ±2 Kb to look for overlaps with 
the CTCF ChIA-PET anchors. In total, we found 4,927 (24.4%) demethylated 
regions overlapping the CTCF ChIA-PET loops, a list of demethylated regions 
with CTCF ChIA-PET loops and their associated genes can be found in 
(Appendix A). This suggests that DNA methylation may work in concert with 
CTCF in a 3-dimensional organization to regulate genes. Close examination of 
a demethylated region Chr19: 42179367- 42319367 (140 Kb) showed 
progressive reduction of DNA methylation from normal to tumor and 
metastasis, within this region CTCF ChIA-PET loops from both colon and 
breast cancer cell lines were observed. Two carcinoembryonic antigens (CEA) 
CEACAM5 and CEACAM6 genes were found to be actively transcribed with 
enriched levels of H3K4me1, H3K4me3 and RNA PolII at their gene promoters. 
Subsequent gene expression profiles also showed increased expression of 
CEACAM5 and CEACAM6 on 44 colon tumors and 21 liver metastases (Figure 
84 
21E). It was found that overexpression of carcinoembryonic antigens had been 
associated with cell invasion and migration causing cancer (Blumenthal et al. 
2005). With CTCF binding peaks surrounding the boundaries and overlapping 
long range CTCF loops within the demethylated regions, we suspect that the 
CTCF looping may either be involved in wrapping CEACAM5 and CEACAM6 
to prevent DNA methylation from silencing the genes or the reverse where DNA 
methylation modulate the binding of CTCF to regulation the expression of the 
genes to drive cell invasion and migration.  
 
Figure 21.Characterization of large demethylated regions in CRC. 
(A) The size distribution of demethylated regions is ranging from 5 Kb to 1.5 Mb. (B) 
Mean methylation levels in demethylated regions during cancer progression. (C) Large 
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demethylated regions were located in regions without CGIs with only 4.16% of the 
regions overlapping CGIs. (D) Demethylated regions compared to non-demethylated 
regions were located in gene poor areas. (E) Chromosome view of CpG methylation in 
normal, tumor and metastasis with demethylated regions (marked in black). An 
example of a progressively demethylated region Chr19: 42179367-42319367 was 
shown. In this region, demethylation was observed in metastasis cells which overlapped 
with two active carcinoembryonic antigens CEACAM5 and CEACAM6 marked by 
active histone marks H3K4me1 and H3K4me3 as well as RNA PolII within upstream 
2 Kb of their gene promoters. In addition, the demethylated regions coincided with 
CTCF ChIA-PET loops in both colon and breast cancer cell lines HCT116 and MCF7, 
respectively. The log2 expression of CEACAM5 and CEACAM6 were based on 44 
normal and tumor colon and 21 liver metastases samples. Presented in a box plot 
showing increased expression of the genes in tumor and metastasis colon. 
Demethylated regions are marked in black.  
 
 
Figure 22. Transcription regulator profile along the large demethylated regions. 
The distribution profile of H3K4me3, RNA Pol II and CTCF ChIP-seq peaks 
constructed from HCT116 cell line were plotted against the large demethylated 
regions (marked in red). The average peaks profile was generated at regions 
within the demethylated blocks as well as regions up to 2 Kb upstream and 
downstream of the demethylated blocks. 
 
DNA methylation correlation with gene transcription during cancer 
progression 
 
To determine the effect of DNA methylation outside the gene promoter 
on gene regulation, we plotted the CpG methylation profiles of all 3 samples 
along a gene model. Here, we classified the gene model into four categories: 
promoter region (10 Kb upstream to 1 Kb downstream of the TSS), intragenic 
region (1 Kb downstream of TSS to 1 Kb upstream of 3’ region), 3’ region (1 
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Kb upstream to 10 Kb downstream from 3’region) and intergenic region (all 
other regions not covered by the above categories). Interestingly, both normal 
and cancer cells shared the same distribution profile with levels of DNA 
methylation exhibit a ‘V’ shape within ± 3 Kb of TSS. Gradual increase in DNA 
methylation was observed at the intragenic regions followed by a dip at TTS 
and increased methylation in the intergenic regions (Figure 23A). We observed 
that regions surrounding ±1.5 Kb of the TSS had the most significant change in 
DNA methylation between normal and cancer cells. Out of the 5 cell types, 
metastasis cells had the most increased CpG methylation at the TSS followed 
by primary tumor, a stark contrast from the global hypomethylation during 
cancer progression. Interestingly, we see decreased methylation in metastatic 
cells at both intra and intergenic regions. We next investigated if the increase in 
CpG methylation at the TSS is related to the presence of CGI promoters. Indeed, 
CpG methylation at TSS was found to be highly associated with CGIs promoter 
with metastatic cells displaying 2 fold increased in CpG methylation from 
normal colon. On the other hand, all three tissues had similar levels of CpG 
methylation at the non-CGI promoters (Figure 23B). To further correlate DNA 
methylation and gene expression levels, we logarithm median-normalized 
expression data from the actual tumor and metastasis tissues and plotted the 
mean methylation levels surrounding ±5 Kb of TSS from the top 10% and 
bottom 10% most differentially expressed genes in tumor and metastasis, 
respectively. Strong inverse correlation was observed between DNA 
methylation and gene expression at the TSS, with the most expressed genes 
having 0.3% to 0.5% of CpG methylation at the TSS in all 3 cell states. In 
contrast, the downregulated genes in tumor and metastasis progressively 
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showed increased CpG methylation at the TSS from 4.43% to 9.14% in 
metastasis cells (Figure 23C). The upregulated genes in tumor and metastasis 
were mainly involved in basic cell maintenance such as metabolic processes and 
protein transportation (corrected p-value = 5.83 x 10-4 to 4.65 x 10-2) while the 
downregulated genes in the cancer cells were involved in cellular growth and 
proliferation and cell death and survival (corrected p-value = 5.60 x 10-13 to 3.65 
x 10-2; IPA Ingenuity systems, www.ingeuity.com) (Appendix B).			
 
Figure 23. DNA methylation correlation with gene expression during cancer 
progression. 
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 (A) CpG methylation profile along a gene model categorized into: promoter (-10 Kb 
to +1 Kb from transcription start site, TSS), intragenic (+1 Kb from TSS to -1 Kb of 
transcription termination site, TTS), TTS (-1 Kb of TTS to +10 Kb of TTS) and regions 
not within any of the above classification were classified as intergenic regions. Gene 
bodies were divided into 100 equal-sized bins. (B) CpG methylation within ±5 Kb of 
TSS genes with or without promoter CpG islands (CGIs). Promoters with CGIs showed 
increased DNA methylation particularly in metastasis cells compared to normal and 
tumor while gene promoters without CGIs had minimal change in CpG methylation 
from normal to cancer. (C) The change in mean CpG methylation levels surrounding 
±3 Kb from the TSS of the top 10% most upregulated and downregulated genes in 
tumor and metastasis. Strong anti-correlation was observed between the most highly 
expressed genes and DNA methylation. 
 
Identification of differentially methylated regions in colorectal cancer   
 
Existing cancer methylome studies had largely focused on the 
comparison between normal and primary tumor, hence DNA methylation 
alterations in metastasis remains poorly characterized. To gain insight to the 
metastasis methylation patterns and identify key regions with differential 
methylation in different cancer states, we performed comparative pairwise 
analyses between the three methylome using normal colon as a reference. 
Differentially methylated regions (DMRs) in tumor and metastasis were 
identified using a sliding window of 2 Kb: the number of methylated Cs in each 
window was calculated. Next, the differences in methylated Cs between each 
window were calculated and plotted in a histogram. Regions with mean 
differences of SD >5 were defined as DMR. Using these criteria, a total of 4,209 
DMRs were identified in tumor and metastasis. To further identify the tumor 
and metastasis specific DMRs, we overlapped the DMRs from both cells and 
defined regions with less than 1 Kb overlap as unique DMRs. In total, 764 
DMRs were unique to tumor (tDMRs) and 2,124 DMRs were unique to 
metastasis (mDMRs) with another 1,061 overlapping DMRs. These unique 
DMRs were further subdivided into hyper or hypo methylated DMRs based on 
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the mean methylation differences, Z-score >5 (Hyper) and Z-score <-5 (Hypo) 
(Figure 24A). Through the analysis, mDMRs register 3 fold more DMRs than 
tDMRs suggesting the metastasis methylome is more different from the primary 
tumor and more methylation changes maybe acquired during cancer 
progression. Next, we characterized the DMRs by annotating the regions to the 
nearest gene (genes located within 5 Kb of a DMR). About 60% of the tDMRs 
and 70% of the mDMRs were associated with genes. In tDMRs, the distribution 
of hypo and hyper DMRs were similar, about 33% of the DMRs were located 
within the intronic and intergenic regions of their associated genes, 13% of 
DMRs within the gene promoter regions and another 10% in the exons and 
CGIs. In contrast, the hyper and hypo mDMRs distribution were less similar, 
64% of the hyper mDMRs were located at gene promoters while only 14% of 
hypo mDMRs were located at gene promoters. We further categorized the gene 
promoters into those with CGIs and those without CGIs. We observed that 60% 
of hyper mDMRs were located at gene promoter with CGIs while hypo mDMRs 
do not show such a bias. Hypo mDMRs relative to hyper mDMRs were more 
highly associated to intron, intergenic and exons regions (~30%) (Figure 24B 
and Appendix C). This suggested that in the metastasis state, more gene 
promoters with CGIs were methylated while the hypomethylated genes had 
increased methylation at the intron regions. This observation is in line with our 
previous observation that highly expressed genes had higher gene body 
methylation while the lowly expressed genes had higher promoter methylation.  
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Figure 24. Identification and distribution of differentially methylated regions in 
tumor and metastasis CRC. 
(A) Total number of identified DMRs in tumor and metastasis CRC. The DMRs were 
further subgrouped into DMRs that were hypermethylated or hypomethylated. (B) 
Distribution of tumor and metastasis DMRs and their associated genomic features.  
 
Through our DMRs analysis, we were able to identify new and 
previously reported hypermethylated promoters in CRC including GATA4, 
GATA5, ITGA4, SFRP1, SPG20 and SOX17 (Caldwell et al. 2004; Du et al. 
2009; Hellebrekers et al. 2009; Chang et al. 2010; Lind GE 2013) which further 
confirmed our analysis is correct and accurate. For instance, GATA5 which was 
found to be methylated in >70% of colon tumor patients and suggested to act as 
a tumor suppressor (Ausch et al. 2009; Hellebrekers et al. 2009) was also 
detected in our analysis with increasing promoter hypermethylation from normal 
to tumor and metastasis at Chr20:61,049,000-61,053,000 (Figure 25A). Similarly, 
ITGA4 which was recently identified as a new biomarker for non-invasive 
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detection of early stages of CRC (Ausch et al. 2009) also showed significantly 
higher promoter methylation levels in metastasis compared to tumor at 
Chr2:182,321,000-182,324,000 (Figure 25B). To verify the methylation status 
observed in the DMRs, we performed bisulfite specific PCR and Sanger 
sequencing (BSP) in both WT and DKO HCT116 at regions surrounding the 
TSS of GATA5 (Chr20:61,051,343-61,051,661) and ITGA4 
(Chr2:182,321,304-182,321,528). In both assays, WT HCT116 was highly 
methylated while DKO is almost unmethylated (Figure 25). This result 
corresponds to the hypermethylation status observed in our DMRs. Therefore, 
confirming our methylation calling and DMRs definition. The details of the 
primer sequences used for BSP validation can be found in (Appendix D). 
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Figure 25. Examples of differentially methylated regions with known CRC related 
genes. 
Examples of hypermethylated DMRs identified through our DMRs analysis and their 
associated CRC known genes (A) Hypermethylated DMR was identified at 
Chr20:61,049,000-61,053,000 within the promoter region of GATA5. Significant 
increase in DNA methylation from normal to metastasis and correspondingly high 
methylation levels in WT HCT116 and depleted methylation in DKO cells were 
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observed. The promoter hypermethylation anti-correlate with active histone mark 
H3K4me3 suggesting that DNA methylation may play a role in silencing GATA5.  (B) 
Promoter hypermethylation of ITGA4 at Chr2:182,321,000-182,324,000 showed 
significant increase in DNA methylation from normal to metastasis as well as WT 
HCT116. ITGA4 increased gene activity was represented by H3K4me3 enrichment and 
RNA-seq profile in DKO cells. Bisulfite specific PCR and Sanger sequencing was 
performed in WT and DKO HCT116 to validate the methylation status of the identified 
DMRs. 
 
Identification of potential genes associated with colorectal cancer 
development and progression 
 
To further discriminate what genes were involved in tumor and 
metastasis CRC, we integrated the unique tDMRs and mDMRs with normalized 
gene expression profiles from public datasets derived from 44 matched colon 
tumor and normal samples and 21 liver metastasis downloaded from GSE41258 
(Sheffer et al. 2009). Since our previous analysis showed that CGI gene 
promoters in metastases correlated with DNA methylation, we examined the 
genes associated with the promoter DMRs and applied a threshold of Z-score 
>5 and expression fold change >1.5 to select for genes with the most significant 
differential methylation and corresponding inversed expression. Sixty-seven out 
of 764 promoter tDMR genes and 715 out of 2,124 promoter mDMR gene 
expression levels can be detected in the public dataset GSE41258. To select for 
genes with the most significant change in differential methylation and 
expression, a threshold of mean differential methylation z-score <-5 or >5 and 
expression fold change ≥1.5 was applied. Based on the above parameters, we 
identified 183 genes with a significant change in methylation and corresponding 
inversed expression from both tDMRs (21 out of 67 genes) and mDMRs (162 
out of 715 genes) (Figure 26A; Appendix E and F). Gene ontology analysis of 
the promoter hypo and hyper methylated genes showed that the promoter 
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hypomethylated genes were enriched in biological processes involved in 
cellular complex assembly and organization, while the promoter 
hypermethylated genes were enriched in cell motion, cell migration and 
regulation of cell proliferation processes (DAVID Bioinformatics Resource 6.7 
(Huang et al. 2009); Table 6).  
Biological processes (Hyper promoter mDMRs) P-value 
cell motion 9.66E-04 
cell migration 1.21E-03 
cell motility 2.36E-03 
localization of cell 2.36E-03 
regulation of cell proliferation 2.51E-03 
cell-cell adhesion 5.11E-03 
cell surface receptor linked signal transduction 5.71E-03 
cell adhesion 6.84E-03 
    
Biological process (Hypo mDMRs promoter genes) P-value 
cellular protein complex assembly 2.60E-02 
protein complex biogenesis 4.20E-02 
protein complex assembly 4.20E-02 
macromolecular complex assembly 8.10E-02 
cellular macromolecular complex assembly 8.60E-02 
macromolecular complex subunit organization 9.50E-02 
Table 6. Gene ontology analysis of promoter hypo and hypermethylated genes. 
 
MST1R, a gene previously reported to be involved in promoting cancer 
cell migration in pancreatic, gastric and breast cancers, was observed in our data 
to undergo promoter hypomethylation from normal colon to tumor and 
metastasis cells (Moser et al. 2012; Wagh et al. 2012). In addition, the 
hypomethylation of MST1R in metastasis cells was accompanied by increased 
upregulation of expression in metastasis relative to normal tissues (p-value= 
5.08E-02) and high enrichment of H3K4me3 in WT HCT116 cells (Figure 25B), 
suggesting that MST1R may be regulated by DNA methylation and potentially 
be involved in cell migration of cancer cells.  
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Apart from the hypomethylated genes, 158 hypermethylated mDMRs 
associated genes was identified which include MPPED2 and ANPEP. 
MPPED2, a metallophosphoesterase was reported to be epigenetically regulated 
by DNA methylation. The gene was down regulated in >50% breast tumors and 
in 20% of breast cancer with lymph node metastases through promoter 
hypermethylation (Seitz et al. 2006). In addition, induced over expression of 
MPPED2 was found to inhibit cell cycle proliferation and impaired 
neuroblastoma tumorigenesis (Liguori et al. 2012). Altogether suggesting 
promoter hypermethylation of MPPED2 may have a role in encouraging tumor 
growth (Figure 26C). Similarly, ANPEP showed significantly higher promoter 
hypermethylation in metastasis compared to tumor. ANPEP is an important 
gene for regulation of cell proliferation and cell migration, which had been 
previously reported to be involved in melanoma cells invasion (Figure 26D) 
(Pasqualini et al. 2000; Mina-Osorio 2008; Wulfänger et al. 2012). The 
promoter methylation status of ANPEP and MPPED2 were validated in seven 
CRC cell lines and five tumor tissues as well as the WT and DKO HCT116 cell 
lines (Figure 26E).  
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Figure 26. Identification of differentially methylated promoter genes with 
corresponding inverse gene expression changes. 
 (A) Correlation of hyper and hypo methylated tDMRs (in green) and mDMRs (in red) 
genes against the differentially expressed genes from tumor and metastasis tissues. A 
threshold of mean DNA methylation differences Z- score >5 or <-5 and a log expression 
ratio (T/N) and (M/N) fold change ≥1.5 was applied (in grey dashed lines). 
Differentially methylated genes from tDMRs and mDMRs within the threshold were 
highlighted in blue boxes. (B-D) Representative examples of hypo and hyper 
methylated genes with corresponding inversed gene expression in tumor cells. (B) 
MSTR1, showed progressive hypomethylation at the gene promoter from normal to 
metastasis cells were marked by high levels of active histone H3K4me3 in WT 
HCT116, with increased gene expression in WT HCT116, tumor and metastasis tissues 
(p-value= 5.08E-02). (C-D) Differentially hypermethylated genes in mDMRs (C) 
ANPEP and (D) MPPED2. Both ANPEP and MPPED2 showed increased DNA 
hypermethylation in metastasis cells marked in light blue with corresponding 
demethylation and increased H3K4me3 marks in DKO cells which demonstrate the 
expression of these genes are regulated by DNA methylation. Down regulation of 
MPPED2 and ANPEP were further confirmed in gene expression array derived from 
44 matched normal and tumor colon and 21 liver metastasis (p-value= 2.33E-04 and 
4.326E-07, respectively). (E) The promoter methylation status of MPPED2 and 
ANPEP were validated using methylation specific PCR (MSP) in 7 CRC cell lines 
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(Caco2, DLD1, HCT116, HT15, LOVO, RKO, SW480) and 5 colon tumor tissues. M: 




Derangement in DNA methylation had been known to be implicated 
with tumorigenesis (Ehrlich 2002). However, little is known of the role of DNA 
methylation and the alterations involved during cancer progression, particularly 
in metastasis. To provide insights to the changes in DNA methylation during 
cancer development and progression, we generated three high resolution single 
nucleotide methylome maps on a set of normal, tumor and metastasis colon 
samples from the same individual to represent the progressive stages of CRC.  
 
Based on our comparative analysis, the cancer genome showed global 
gain in DNA hypomethylation with cancer progression. Out of which, 
metastatic cells had the most reduction in CpG methylation. We also further 
confirmed that these hypomethylated regions were non-randomly distributed in 
the genome but rather located within local clusters that can span up to 0.12 Mb 
in agreement with previous reports (Hansen et al. 2011). In addition, we 
observed high correlation of hypomethylation at LINE1 and LINE2 repeats with 
increased cancer malignancy (p-value <5.63E-05). Our results on LINE1 
hypomethylation with increased cancer malignancy was also supported by 
previous studies that CRC patients with LINE1 hypomethylation showed the 
worst prognosis (Ogino et al. 2008). However, the impact of LINE2 as well as 
ERV hypomethylation in relation to poor cancer prognosis remains to be 
investigated. In contrast to the global hypomethylation in cancer genome, 
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metastatic cancer increasingly showed gained in DNA methylation at regions of 
the promoter as well as the exons. In particular, promoter CGIs methylation was 
often inversely correlated with gene expression and involved in transcriptional 
silencing. By integrating the DMRs identified between normal, tumor and 
metastasis CRC with gene expression profile, we identified potential new 
candidates involved in tumor development such as MPPED2, and SLFN13 as 
well as ANPEP and MMRN1 for tumor progression. However, the biological 
functions and the clinical usage of these candidate genes requires further 
investigation. Our analysis demonstrated that global DNA methylation patterns 
in metastasis largely followed the matched tumor. However, the metastatic cells 
compared to tumor acquired amplified levels of local directional DNA 
methylation changes particularly, at the promoters. For instance, BNIP3 and 
PCDH8 involved in CRC progression were observed to acquire de novo DNA 
hypermethylation at the gene promoter in metastatic CRC (Yu et al. 2008; Liu 
et al. 2011). In contrast, MYEOV involved in CRC cell migration showed loss 
of promoter DNA methylation in metastatic CRC compared to colon tumor 
(Lawlor et al. 2010) 
 
In conclusion, our comprehensive analysis of the CRC methylome 
throughout tumor development and progression has identified important regions 
of differential methylation between tumor and metastasis. These differential 
methylated regions upon integration with gene expression can be used to 
identify potential candidate biomarkers involved in development and 
progression of cancer malignancies (Figure 27). Nevertheless, it remains 
unclear what are the regulators or mechanisms involved in regulating the local 
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DMRs changes and the large hypomethylated regions. The understanding of the 
regulators involved in the local methylation changes can provide new insights 
to improve existing epigenetic therapies for more specific re-activation and 
inactivation of the tumor suppressors and oncogenes, respectively. This is 
because existing DNA methylation inhibitors such as 5-aza-2′-deoxycytidine 
(5’-AZA-dc) for cancer therapy acts on a global scale to inhibit DNA 
methylation thus, reactivating the silent tumor suppressors to suppress 
tumorigenesis (Momparler 2005). However, this can risk the activation of 
oncogene counteracting the suppression of tumorigenesis. Therefore, we 
suggest that future works should look into the mechanisms involved in 
regulating these local DMRs.  
 
Figure 27. Overview of global DNA methylation changes at different state of 
cancer progression. 
Global DNA methylation profile during cancer progression is highly dynamic, genome 
wide reduction in DNA methylation was observed throughout cancer progression from 
normal to tumor and metastasis. In contrast, increased DNA methylation was observed 
with increased malignancy at the transcript levels particularly at gene promoter 
associated with CpG islands. More interestingly, local hypermethylation were observed 
during the transition from tumor to metastasis. Such epigenetic changes may result in 
unstable chromosome stability and gene regulation contributing to the increased gene 
alteration during cancer. 
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Materials and Methods  
Note: All experiments, data analysis and data interpretation were performed by myself 
unless otherwise stated at the bottom of each section of the materials and methods.  
 
Clinical samples and cell culture 
 
A set of matched normal colon mucosa, primary tumor and synchronous 
liver metastasis gDNA from a consented 59 year-old male individual diagnosed 
as stage T3N2 with no KRAS mutation was provided by Dr Francisco J. 
Carmona (Bellvitge Biomedical Research Institute). The human colorectal 
cancer cell line (HCT116) was purchased from ATCC and HCT116 cells with 
genetically disrupted DNMT1 and 3B (DKO) was a kind gift from Dr Bert 
Vogelstein (John Hopkins University ) (Rhee et al. 2002). The WT and DKO 
HCT116 cells were used to compare the gene expression in the presence or 
absence of DNA methylation. The cells were cultured in DMEM medium 
supplemented with 4.5mM glucose and 10% heat inactivated FBS (Life 
Technologies) at 37C in a humidified atmosphere of 5% CO2. DNA were 
extracted and purified from the cell lines using Genomic DNA buffer set 
(Qiagen) and quantified against Nanodrop. Note. DKO cells were cultured and 
prepared by Dr Tan Jing, Genome Institute of Singapore, Singapore.   
 
Whole genome bisulfite sequencing (WGB-seq) library construction 
 
Five WGB-seq libraries were constructed using gDNA from the matched 
normal colon mucosa, primary tumor and synchronous liver metastasis as well 
as WT and DKO HCT116 cells. Briefly, 3-5 µg of purified gDNA from each 
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sample were randomly sheared at 40psi for 1min using nebulization (Illumina, 
Inc) to obtain average DNA sizes between 300-700 bp. The sheared DNA was 
end polished followed by 3’ A-tailing and ligated with methylated PE adapters 
to both ends of the DNA. The adapter-ligated DNA was treated to two rounds 
of consecutive bisulfite treatment using EpiTect Bisulfite Kit (Qiagen). The 
bisulfite converted DNA was subjected to 6 cycles of PCR amplifications using 
a final concentration of 0.1 U/µl Pfu TurboCx Hotstart DNA polymerase 
(Stratagene) to reduce PCR redundancy. The amplified DNA was run in 2% 
agarose gel and a smear fraction between 200-300 bp was excised. The DNA 





1µg of DNA from the same matched normal colon, primary tumor and 
colon with liver metastasis used for WGB-seq were subjected to bisulfite 
treatment using EZ DNA methylation kit (Zymo Research). The bisulfite 
converted DNA was hybridized onto the 27K BeadArrays according to the 
manufacturer’s instructions. The data was analyzed using Beadstudio software 
(Illumina, Inc) to generate the methylation scores from the image intensities. 
The methylation scores were normalized and averaged for subsequent analysis. 
Note. The HumanMethylation27 BeadArray data was provided by Dr Tan Jing, 
Genome Institute of Singapore, Singapore.   
 
 ChIP-seq library generation and sequencing 
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ChIP-seq libraries were constructed and modified accordingly with 
reference to (Chen et al. 2008). Briefly, HCT116 cells were cross-linked with 
1% formaldehyde, washed with PBS and lysed in 1% SDS. Chromatin was 
collected and sonicated to fragments between 300 to 500 bp using Bioruptor 
(Low, 30 sec on and 30 sec off for 5 min). The chromatin was 
immunoprecipitated with the respective antibodies: anti-histone H3 trimethyl 
K4, H3K4me3 (Abcam ab8580), anti-histone H3 monomethyl K4, H3K4me1 
(Abcam ab8895-50), anti-RNA polymerase II (Pol II) (Covance, MMS-126R) 
and anti-CTCF (Abcam ab70303). The immunoprecipitated chromatin was 
reverse cross-linked to obtain the ChIP-DNA. To construct a ChIP-seq library 
compatible for sequencing on Genome Analyzer IIx (Illumina, Inc), 10 ng of 
ChIP-DNA was used and prepared using Illumina ChIP-seq library preparation 
kit. ChIP-DNA was end polished using Klenow DNA enzyme followed by 3’ 
A-tailed using dATP and Klenow (3’ to 5’ exo minus) (Illumina, Inc). The 
addition of ‘A’ base at the 3’-end enable the ligation of the sequencing adapters 
with a ‘T’ overhang. Illumina single read sequencing adapters were ligated to 
the ends of the DNA using DNA ligase. The adapter-ligated DNA was subjected 
to PCR amplification using PCR primer 1.1 and 1.2 with 1U of Pfx polymerase 
(Life Technologies). The PCR program used for amplifying the adapters-ligated 
DNA was :(1) 94C for 5 min; (2) 15 cycles of 94C for 15 s; (3) 55C for  30 
s; (4) 68C for 60 s; followed by 4C forever. The amplified DNA was run in 
2% ultra-low range agarose and a smear between 200 to 300 bp was excised. 
The DNA samples were sequenced using Illumina Genome Analyzer IIx up to 
readlength of 36bp. Note. H3K4me3 ChIP-seq in DKO cells was prepared by Dr Tan 
Jing, Genome Institute of Singapore, Singapore. H3K4me3 and Pol II ChIP-seq in WT 
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HCT116 cells were prepared by Ms Sim Huishan, Genome Institute of Singapore, 
Singapore. CTCF ChIP-seq in WT HCT116 was prepared by Dr Zheng Meizhen, 
Genome Institute of Singapore, Singapore. 
 
RNA-seq library generation and mapping 
 
Total RNA was extracted from WT and DKO HCT116 cells using Trizol 
RNA (Life Technologies). To prevent ribosomal RNA (rRNA) contamination, 
total RNA was treated with RiboMinus (Life Technologies) to deplete the 
rRNA. The RNA-seq library was prepared using SOLiD Total RNA-seq kit 
(Life Technologies). Briefly, rRNA depleted total RNA was fragmented using 
RNase III, 1 µl of fragmented RNA was run in RNA 6000 Pico Chip Kit 
(Agilent Technologies) to ensure a median size between 125 to 200 bp was 
obtained. Next, SOLiD Adapters were ligated to the ends of the RNA followed 
by reverse transcription to transcribe the rRNA-depleted total RNA into cDNA 
using ArrayScript Reverse Transcriptase. The PCR program used for amplifying 
the cDNA was :(1) 95C for 5 min; (2) 15 cycles of 95C for 30 s; (3) 62C for  
30 s; (4) 72C for 30 s and 72C for 7 min. The amplified DNA was purified 
using PureLink PCR Micro Kit (Life Technologies). 1 µl of DNA was run in 
DNA 1000 kit (Agilent Technologies) to ensure the library had a median size of 
200 bp. The amplified DNA was sequenced using SOLiD platform up to 
readlength of 51bp. Note. WT HCT116 RNA-seq library was constructed by Ms 
Andrea Ho, Genome Institute of Singapore, Singapore.  
 
Methylation specific PCR (MSP) 
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To determine whether a gene promoter is methylated or unmethylated, 
MSP was performed. In each MSP reaction, two sets of primers were designed 
over the same loci: (1) All CpGs in primers were assume as methylated after 
BS-treatment (M); (2) All CpGs ‘C’ in primers were converted to T to represent 
an unmethylated state after BS-treatment to detect regions with unmethylated 
CpGs (U). Primers were designed using Methprimer; 
(http://www.urogene.org/methprimer/index1.html) and synthesize from (1st Base). 
20 ng of BS-treated DNA was used in each MSP PCR reaction using 1U 
KAPA2G Robust DNA polymerase (KAPA Biosystems). The PCR program for 
MSP amplification was: (1) 95C for 3 min; (2) 35 cycles of 95C for 30 s; (3) 
56C for 30 s; (4) 72C for 60 s and a final extension at 72C for 60 s; and 4C 
forever. 12.5µl of PCR product was run in 1% agarose gel for visualization of 
the PCR product.  
 
Bisulfite PCR (BSP) and Sanger sequencing   
 
To quantitatively measure the methylation levels of a specific region of 
interest, bisulfite PCR reaction was performed using 10 ng of BS-converted 
DNA and amplified using 1U of KAPA2G Robust DNA polymerase (KAPA 
Biosystems). (Note: Primers were designed using Methprimer 
(http://www.urogene.org/methprimer/index1.html) under the BSP primers 
parameters. The PCR program used for BSP amplification was: (1) 95C for 3 
min; (2) 35 cycles of 95C for 30 s; (3) 56C for 30 s; (4) 72C for 60 s and a 
final extension at 72C for 60 s and 4C forever. The PCR product was run in 
1% agarose gel and the band was excised using QIAquick gel extraction kit 
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(Qiagen). 4µl of purified PCR product were cloned in pCR 2.1-TOPO TA vector 
(Life Technologies) and transformed into TOP10 electro competent cells (Life 
Technologies). The cells were plated onto LB agar plate with Kanamycin (50 
mg/ml) antibiotics (Sigma Aldrich) and incubated overnight (20hours) at 37C. 
20 clones were randomly picked from the agar plate for subsequent colony PCR 
using 0.5 U Taq polymerase (Qiagen) as previously describe (See Materials and 
Methods for Chapter Two). The resulting PCR products were sequenced using 




To validate the quality of the ChIP, primers targeting the promoters of 
actively expressed genes regulated by H3K4me1, H3K4me3 and Pol II in WT 
and DKO HCT116 cells were designed using Universal ProbeLibrary Assay 
Design Center (Roche) (https://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp?id=UP030000). ChIP DNA prepared from 
HCT116 cells against H3K4me1, H3K4me3 and Pol II were reverse cross-
linked under conditions of 1% SDS and 65°C, and purified using a PCR 
purification kit (Qiagen). ChIP-qPCR was performed using real-time PCR 
quantification with Sybrgreen master mix (Roche). At least two biological 
replicates were performed for each primer pairs.   
 
Data analysis 
BSP data analysis 
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Raw sequences generated from the BSP clones first undergo base calling 
and quality filtering to trim off nucleotides with poor quality (Qscore <20) using 
Sequence Analysis Software version 5.2 (Applied Biosystems). Genomic 
sequences of the PCR amplified region were extracted from UCSC browser, 
hg19. Individual BSP clones trimmed sequences were aligned and analyzed 
using BiQ Analyzer version 2.0 software (Bock et al. 2005). In BiQ Analyzer, 
clones with sequence identity lower than 80% from the reference sequence and 
clones with duplicated sequences were filtered. Only the pass filtered sequences 
were included for subsequent analysis. Percentage CpG methylation was 
calculated at each CpGs site within the PCR region in a ratio from 0 to 100% 
and visualized in “lollipop” charts. Examples of the BSP data were expressed 
in Figure 26.   
 
Whole genome bisulfite sequencing data alignment 
 
The raw WGB-seq reads generated from Genome Analyzer (Illumina) 
were processed using Ilumina ELAND software for base calling and quality 
filtering. Reads that passed filter were used for subsequent alignment to human 
reference genome (hg19) using Basic Alignment Tool for Methylation 
(BatMeth) program (Lim et al. 2012). Compared to SOAP2 (seed-and-harsh) 
approach where a bisulfite read is mapped to the reference within a user-defined 
k seed length followed by hashing. Such alignment algorithm will require large 
computer memory space hence, longer mapping time. To overcome the issue, 
we developed BatMeth a more efficient and accurate bisulfite alignment 
program that can align both the base-read and color reads generated from 
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Illumina and SOLiD, respectively. The BatMeth program aligned the bisulfite 
reads to the reference genome in the following four steps: (1) Converted 
reference genome, two converted reference genome were created one for the 
sense strand and the other for the anti-sense strand. In the sense strand, all Cs in 
the genome were converted to Ts while all Gs in the anti-sense strand were 
converted to As. Indexing of the two converted reference sequences were 
performed using Burrows-Wheeler transform (BWT) before proceeding with 
mapping with up to 2 bp mismatches. (2) Low complexity bisulfite reads 
filtering, to increase the mapping accuracy bisulfite reads with a differential 
entropy H < 0.25 computed using Shannon’s entropy were removed. (3) 
Counting hits, bisulfite reads with an incorrect mapping orientation as well as 
reads with multiple mapping locations were compiled in a hit list. (4) List 
filtering, to increase the mapping efficiency and accuracy bisulfite reads with 
hits >40 were discarded leaving behind high quality reads for alignment. Using 
the mapped locations, the reference genome was reverted to the original form to 
identify the methylated Cs. Methylated Cs is differentiated from the 
unmethylated Cs if the original C in the read remained unchanged. The 
methylation status of a C was calculated based on the number of reads called 
mC over the number of reads called Cs or Ts and expressed in a frequency ratio 
from 0 to 100% into one of the following three categories: Methylated (M > 
60%), partially methylated (20% <, P, >= 60%), and lowly methylated (L < 
20%). To ensure data accuracy, non-unique alignments are discarded and only 
Cs supported by 3 or more reads were used for all subsequent analysis. Note. 
WGB-seq data alignment to reference genome and methylation calling were processed 
by Mr Lim Jing Quan, National University of Singapore, Singapore. The WGB-seq 
data can be downloaded from NCBI GEO database under ID: GSE46540. The library 
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IDs for each tissue type is as follows: normal colon (WHC005), tumor (WHC003), 
metastasis (WHC004), HCT116 (GHH005) and DKO (GHH004). 
 
Gene expression analysis 
 
44 matched normal colon and primary tumor colon and 21 liver 
metastasis  expression profile were downloaded from GSE41258 (Sheffer et al. 
2009). The expression profile was normalized and log2 transformation. To 
obtain the differential tumor genes we calculated the log ratio by taking tumor 
over normal and for differential metastasis genes we calculated the log ratio of 
metastasis over tumor. A threshold of fold change 1.5 was further applied to 
determine the up or downregulated genes in tumor and metastasis cells. Note. 
Gene expression array normalization was performed by Dr Li Guoliang, Genome 
Institute of Singapore, Singapore.     
 
Identification of differentially methylated regions (DMRs) 
 
DMRs between normal, tumor and metastasis colon were identified by 
screening the genome with windows of 2 Kb. Differences in methylation 
between each window of the compared tissues were calculated and the 
distributions of the mean differences were plotted in a scatter plot. A region is 
defined as a DMR if the difference in methylation is >5 standard deviations (SD) 
from the mean methylation differences. DMRs with >5 SD are defined as Hyper 
DMRs while DMRs with <-5 SD are classified as Hypo DMRs. The identified 
DMRs were annotated to the nearest gene features by using the center of the 
DMRs against the gene features. Promoter DMRs were centered (±2.5 Kb) to a 
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TSS, distal promoter were centered (-2.5 Kb to -20 Kb) to a TSS, exon, introns 
as well as intergenic regions. Gene Ontology (GO) analysis was performed on 
the three sets of DMRs genes using Panther Classification System (Thomas et 
al. 2003), with Bonferroni correction for multiple testing of pathway, biological 
processes and molecular functions with p-value < 0.01. Note. Identification of 
differentially methylated regions was performed by Dr Li Guoliang, Genome Institute 
of Singapore, Singapore.     
 
Identification of large demethylated regions 
 
To identify the large demethylated regions in cancer cells across the 
genome, a sliding window of 5 Kb was used. Windows with CpG methylation 
≥ 50% and at least 20% reduction in CpG methylation in metastasis cells were 
classified as de-methylated regions. Neighboring regions ≤ 2 Kb apart with 
similar mean methylation differences were merged to form the final large de-
methylated regions. Note. Identification of large demethylated region was performed 
by Dr Li Guoliang, Genome Institute of Singapore, Singapore.     
 
RNA-seq analysis  
 
RNA-seq enables the identification of known and novel transcript 
expression as well as discovery of gene functions. To align the raw reads 
generated from SOLiD platform, BioScope 1.3 software 
(http://lifetechnologies.com/lifescope) was used to align the reads to the reference 
genome, hg19. In Bioscope, the raw reads were mapped to the reference genome 
using a seed-and-extend approach with user defined seed length at up to two 
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mismatches. The reads were further aligned to the known and putative splice 
junctions and exons regions. Next, the number of reads (tags) covering the 
Refseq transcripts and exons were calculated. The higher the tag counts 
represent higher expression intensity. Note. The RNA-seq data was processed by 
Ms Pauline Chew Jieqi, Genome Institute of Singapore, Singapore.    
 
ChIP-seq data 
Note: ChIP-seq data alignment was processed by Mr Chan Chee Seng and Dr Li 
Guoliang performed the MACS peak finding, Genome Institute of Singapore, 
Singapore. 
 
H3K4me1, H3K4me3, RNA Pol II and CTCF ChIP-enriched DNA 
fragments were sequenced using Illumina single read sequencing analysis and 
aligned onto the Hg19 human reference genome. In total, 16,292,277 unique 
reads were sequenced for H3K4me1, 12,427,028 unique reads for H3K4me3, 
11,187,160 unique reads for RNA Pol II and 20,249,534 unique reads for CTCF. 
Enrichment peaks for each target protein were identified using the default peak 
finding parameters from Model-based Analysis of ChIP-seq (MACS) 
(http://liulab.dfci.harvard.edu/MACS/) (Zhang et al. 2008). Using a cutoff of FDR 
< 0.05, a total of 54, 536 H3K4me1 peaks, 17, 583 H3K4me3 peaks, 33,583 




Chapter Four: Conclusions 
 
In this thesis, I have successfully generated genome wide methylation 
maps of undifferentiated hES and CRC at single nucleotide resolution. Using 
these high resolution methylome maps, I have addressed one of the major 
questions on the regulation of human epigenome in normal and cancer state: 
What is the distribution pattern of DNA methylation in normal and cancer cells? 
Secondly, how does DNA methylation which is located at different genomic 
regions affect gene regulation? In addition, I examined the DMRs and their 
associated genes involved in hESC differentiation and CRC to search for 
candidate marker genes with potential clinical applications. Through this study, 
global increased in CpG methylation was observed in hESCs differentiation but 
in cancer CpG methylation decreased with increased cancer malignancy. The 
change in methylation patterns suggests that an increased CpG methylation may 
commit the hESCs for cell type specific differentiation and once differentiated, 
prevents the differentiated cells from differentiating into other cell types. In 
contrast, the reverse CpG methylation trend in cancer development may aid in 
resetting the pre-programmed methylation patterns in adult colon to assume a 
de-differentiated state alike hESCs. The derangement in methylation may cause 
the normal colon cells to lose its cell proliferation control properties resulting in 
uncontrolled cell growth. By further examining the CpG methylation patterns at 
different genomic features, it was found that CpG methylation at TSS is anti-
correlated with gene expression, while methylation at the gene body is 
positively correlated with gene expression. Hence, suggesting that the high 
methylation levels at TSS may block out active transcription factors from 
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accessing the promoter to initiate transcription, and stable gene silencing may 
be maintained by lower levels of methylation throughout the gene body and TTS 
regions. Similarly, lower levels of methylation at TSS as well as anti-correlation 
with active H3K4me3 binding may allow for easier access of the regulatory 
elements to the promoter for transcription initiation, while a higher level of gene 
bodies methylation may interfere with less productive transcription initiation 
within the regions to improve the transcription efficiency of actively transcribed 
genes (Ball et al. 2009). By comparing the methylation profile between the 
different cell states, many unique DMRs were identified. Upon integration with 
genome wide gene expression array lead allow the identification of potential 
markers involved in cell pluripotency or differentiation as well as genes 
involved in cell invasion and proliferation that aid cancer progression. Given 
the wide implications of DNA methylation in human health, this study model 
can be applied to any cell types to characterize the unique cell specific 
methylation patterns and identify specific DMRs and gene for understanding a 
specific biological process. Although WGB-seq enables the identification of cell 
type specific DMRs and their associated genes, it remains expensive to sequence 
a range of tissues or cell types at high sequencing depth. Hence, moving forward 
it will be more cost effective to design customized array panel which contain 
the key cell-type specific or disease specific DMR loci identified in WGB-seq 
studies. Together these global and high-definition approaches which enable the 
investigation of cross-talk between DNA methylation and other epigenetic 
marks shall revolutionize the study of epigenomics.  
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Future directions of DNA methylome studies with improved detection 
technologies  
 
Since the development of NGS technologies, the study of DNA 
methylome has changed dramatically from a single locus to whole genome 
studies enhancing our understanding on the field of epigenetic (Weber et al. 
2005; Lister et al. 2009; Laurent et al. 2010). Out of the multiple techniques 
available, bisulfite treatment has emerged as the gold standard for unbiased 
detection of 5mCs where subsequent coupling with NGS technologies enabled 
single base resolution detection. In 2009, a sixth DNA modification molecule 
called 5-hydroxymethylcytosine (5hmC) was detected in high abundance in 
hESCs and subsequently in Purkinje neurons (Kriaucionis and Heintz 2009; 
Tahiliani et al. 2009). It was further determined that the conversion of 5mC to 
5hmC involved the TET proteins which are responsible for ESC regulation and 
zygote development. This has thus generated a widespread interest to 
understand the role of 5hmC in development and its interplay with 5mC for gene 
regulation. However, the study of 5hmC had been limited due to the lack of 
sensitive and quantitative detection techniques. Although WGB-seq has enabled 
the identification of 5mC at single base resolution, it is unable to differentiate 
between 5mC and 5hmC due to their structural similarity. Hence, for a particular 
nucleotide position detected as 5mC in WGB-seq, the true modification may in 
turn be a 5hmC. This is because in bisulfite conversion both 5mC and 5hmC are 
resistant to deamination resulting in both modifications to remain as C after 
bisulfite conversion (Huang et al. 2010). Therefore, new technologies are 
required to distinguish the two DNA methylation modifications. Using the 
principle of MeDIP-seq, commercial 5hmC antibody was used to enriched DNA 
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with 5hmC then coupled with NGS for genome wide 5hmC detection (Ficz et 
al. 2011). However, like most affinity based methods the sensitivity of the 
technique is highly dependent on the quality of the antibody. Moreover, the 
method is unable to detect the relative abundance of the modification at single 
base resolution.  
 
Until recently, two independent groups developed two genome wide 
5hmC single base resolution detection methods through modification of 
traditional bisulfite conversion called oxidative bisulfite sequencing (OxBS-
seq) (Booth et al. 2012) and TET-assisted bisulfite sequencing (TAB-seq) (Yu 
et al. 2012). In OxBS-seq, 5hmC is oxidized to form 5-formylcytosine (5fC) 
using potassium perruthenate (KRuO4). Subsequently, 5fC was decarbonylated 
and deaminated to form uracil (U) during bisulfite conversion. Thus, in OxBS-
seq, original 5hmC is converted to U while 5mC remains as C. The location and 
relative amount of 5hmC can be detected by subtracting the WGB-seq readout 
(Booth et al. 2012). Using this method, Booth and colleagues completed the 
mouse ES cells 5hmC profile where 5hmC was detected exclusively to CpG 
dinucleotides and enriched in intragenic regions. In TAB-seq, β-
glucosyltransferase (βGT) was used to add glucose onto 5hmC to generate β-
glucosyl-5-hydroxymethylcytosine (5gmc) to prevent 5hmC from TET 
oxidation. Subsequently, 5mC was converted to 5-carboxylcytosine (5caC) 
through TET oxidation which upon bisulfite treatment act like an unmethylated 
cytosine which gets converted to uracil while the original 5hmC that was 
protected as 5gmc upon sequencing will reveal as C (He et al. 2011; Ito et al. 
2011). Hence, by combining traditional bisulfite sequencing and TAB-seq the 
115 
position of individual 5mC and 5hmC can be revealed at single base resolution. 
Using TAB-seq, Yu and colleagues characterized both human and mouse 5hmC 
profiles. Similar to the previous observation by Booth et al, 5hmC was found to 
occur primarily in CpG dinucleotides in both mouse and human ES cells. But 
different from methylated CpG, these 5hmC exhibit asymmetric strand bias 
within G-rich context (Stroud et al. 2011). In addition, compared to 5mC, distal 
regulatory regions and gene bodies were highly enriched with 5hmC (Yu et al. 
2012). Together with the development of oxBS-seq, TAB-seq and WGB-seq, 
we can now accurately locate the position of 5mC and 5hmC in all cell types 
and tissues to decipher the roles of these DNA modifications and their interplay 
with other epigenetic marks in development and diseases.    
 
Despite the advances in WGB-seq, TAB-seq and oxBS-seq, these 
methods involved harsh chemical treatment which may result in high DNA 
damage and therefore required larger amount of starting DNA material. This 
may pose as a challenge in processing patient’s tissues samples which are 
normally available in low quantity. Furthermore, the requirement for 
statistically significantly sequencing depth coverage will contribute to high 
sequencing cost. Thus, high throughput direct detection of DNA methylation 
with minimal chemical modification will be the most ideal.  
 
Recent developments in third generation sequencing technologies such 
as single molecule real time sequencing (SMRT) and nanopore sequencing 
technology enables the parallel detection of primary sequences and DNA 
chemical modifications in real time (Flusberg et al. 2010; Cherf et al. 2012). In 
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SMRT technology, the incorporation of fluorescently labeled nucleotides 
complementary to the template DNA was observed at real time through single 
DNA polymerase molecules. Each nucleotide is represented by a unique 
fluorescence color and with every nucleotide incorporation a pulse of 
fluorescence was detected. Upon incorporation of the nucleotide, the 
fluorophore linked to the nucleotide’s terminal phosphate is cleaved by the 
polymerase before reading the next base in the template. Next, different DNA 
modifications can be detected based on the changes in fluorescence pulses. The 
duration of a pulse and the interval between each successive pulse are tabulated 
in a metrics defined as pulse width and interpulse duration (IPD). Changes to 
the IPD metric affect the polymerase kinetics which is used to determine the 
different DNA modifications including 5mC and 5hmC. Using this technology, 
the first single molecule, direct DNA methylation detection at real time 
sequencing was performed in 2010 by Flusberg et al. Using synthetic DNA that 
contained N6-methyladenine (6mA), 5mC and 5hmC, they were able to 
differentiate between the individual DNA modifications through the IPD ratio 
between two sequences at real time (Flusberg et al. 2010). The SMRT 
technology is particularly useful for DNA methylation studies in organisms such 
as plants and bacteria which contain more methylation apart from 5mC and 
5hmC. Furthermore, the technology allows the identification of novel DNA 
methylation modifications since the method is not biased towards any specific 
methylcytosine but a direct read of bases by the change in the polymerase 
kinetics. Despite promising results, the SMRT sequencing system is still in its 
early stages of development and there are still many technical hurdles that needs 
to be overcome. For instance, the current platform detection sensitivity of 5hmC 
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is low hence, additional modifications are required to enrich for 5hmC before 
detection defeating the purpose of having direct DNA methylation detection. 
Furthermore, the current application of SMRT on larger eukaryotes such as 
mouse or human is still a challenge. More improvements are required on the 
SMRT technology before it can become a robust platform for a wide spectrum 
of applications in particular in larger genomes.   
 
For now, WGB-seq has revolutionized the way we study DNA 
methylation and dramatically reduced the sequencing cost and increased the 
resolution to allow the discovery of novel DNA modifications which are 
increasingly understood to be biologically important. Thus we can expect to see 
the emergence of more robust and distinctive technologies that can differentiate 
5hmCs from 5mCs at high resolution.   
 
Clinical applications of DNA methylation   
 
To date many large scale DNA methylation studies had been performed 
by different groups in various tissues including our group where we mapped out 
the changes in DNA methylation during CRC progression and hES 
differentiation. Out of which, we had identified epigenetically regulated known 
CRC related genes and pluripotency markers. At the same time, many new 
potential candidate genes that were involved in CRC development and 
progression such as ANPEP and MPPED2 were also identified. However, the 
biological functions of these candidate genes remain to be determined. 
Nevertheless, existing studies had demonstrated that the differentially 
methylated genes detected in various cancers can be made into biomarker for 
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early stage cancer detection and further shown as therapeutic targets to deter the 
growth of cancer cells. Here, I discuss how different epigenetically regulated 
cancer related genes can be translated into diagnostic or therapeutics purposes.   
 
Diagnostic    
 
With increased genomic resolution and epigenetic profiling, the 
methylation patterns in various cancers had been revealed including colon, 
breast and gastric cancer (Irizarry et al. 2009; Hon et al. 2012; Simmer et al. 
2012; Zouridis et al. 2012). The identified DNA methylation alteration had 
since been applied to cancer diagnostics. Compared to genetic variations, DNA 
methylation alterations occur at higher frequency in tumors giving a higher 
sensitivity, hence more advantages for clinical applications (Esteller et al. 
2001). Early detection is one of the key features to reduce CRC mortality 
(Winawer et al. 2003; Baxter et al. 2009). However, patient compliance to 
existing CRC screening methods such as lower bowel optical colonoscopy and 
sigmoidoscopy and fecal occult blood test (FOBT) remains low. The former 
which involved the insertion of a flexible tube through the rectum to the large 
intestines is invasive, costly and cumbersome to the patient. In which, patients 
are required to follow a specific diet to wash out the intestines a night before the 
scan can take place. On the other hand, FOBT requires the collection of stool 
samples for testing. Hence, the development of cheaper, non-invasive and 
sensitive detection methods such as blood-based test which can be incorporated 
into routine health screening are highly sought after.  
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Tumor DNA can enter biological fluids in several ways; direct released 
of tumor cells from the tissue of origin; tumor cells engulfed by macrophages 
which enter the blood or free tumor DNA released into the body fluids by cell 
lysis (Heyn and Esteller 2012). Given that aberrant DNA methylation occurs 
frequently in cancers which can be detected in circulation of cancer patients, it 
represents a rich source of potential biomarkers for non-invasive detection 
methods (Chan et al. 2008; Grady and Carethers 2008). For instance, three 
potential DNA methylation biomarkers, TMEFF2, NGFR and SEPT9 identified 
through methylation sensitive restriction enzyme based method combined with 
microarray and real-time PCR analysis were validated with plasma samples 
from 133 CRC patients and 179 normal colon. Out of the 3 markers, SEPT9 
methylation was detected in 69% of CRC patients and not detected in 86% of 
normal colon. More importantly, SEPT9 was detected in circulating plasma of 
cancer patients which make it a favorable candidate for non-invasive methods 
(Model et al. 2007; Lofton-Day et al. 2008). Methylated SEPT9 as blood based 
CRC biomarker was validated in 133 CRC patients (stage I-III) and 179 healthy 
individuals for its sensitivity and specificity (Lofton-Day et al. 2008). The 
results were further confirmed in two independent studies that screened 97 and 
50 CRC patients, respectively. With the former giving a sensitivity of 72% and 
specificity of 90% and the latter at 90% sensitivity and a specificity of 88% 
(deVos et al. 2009; Warren et al. 2011). These results demonstrate that 
methylated SEPT9 is a sensitive and specific blood test for early CRC detection. 
The sensitivity and relative ease of blood-based tests can be incorporated into 
routine physical examinations and patients tested positive in the blood tests can 
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be followed up with colonoscopy for early CRC detection, thus reducing the 
mortality of the disease.  
 
Targeted epigenetic drugs    
 
Increased resolution of epigenetic profiles not only benefited the 
identification of specific biomarkers for diagnosis but also open doors for 
targeted epigenetic treatments. Such treatments are likely to improve the 
performance and reduce the toxicity of current cancer drugs and will help to 
achieve personalized treatment. Currently, the approved epigenetic treatments 
include DNA methyltransferase (DNMT) inhibitors; 5-azacytidine (5-aza-CR) 
(Fenaux et al. 2009) and its variant 5-aza-2’-deoxycytidine (5-aza-CdR) and 
histone deacetylase (HDAC) inhibitors; vorinostat and romidepsin. DNMT 
inhibitors (DNMTIs) work by incorporating itself into the DNA which trap the 
DNMTs and inactivate the protein- DNA interaction. This results in rapid DNA 
methylation reduction in the genome as the cells continue to undergo cell 
replication (Lyko and Brown 2005). For instance, in a phase I clinical trial, 5’-
aza-CR was administrated daily to CRC patients over 10 days. Global DNA 
methylation was significantly reduced in peripheral blood mononuclear cells 
where 25% of the patients showed disease stabilization (Braiteh et al. 2008). On 
the other hand, low doses of DNMTIs showed reactivation of methylated tumor 
suppressor genes (Schrump et al. 2006). However, such effect is only transient 
and can be reversed upon suspending the administration of the drugs which 
limits the use of these drugs as a single treatment agent in solid tumors. 
Furthermore, such global demethylation may lead to the activation of oncogenes 
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which can risk in aggravating the disease.  Hence, a new generation of 
epigenetic treatments with more specific targets is required for successful 
treatments.  
 
The sensitivity to chemotherapeutic drugs is variable between individual 
and tumor types, hence if we can better predict the response of each patient to a 
given chemotherapy it will increase the efficiency of the treatment. Through 
epigenetic profiling, differentially methylated genes had been identified as 
tumor specific drug response markers. For example, glioblastoma patients with 
MGMT promoter hypermethylation and MGMT gene silencing had been found 
to be more sensitive to alkylating chemotherapies such as temozolomide and 
carmustine (Esteller et al. 2000; Hegi et al. 2005). MGMT gene encodes for a 
DNA repair protein to remove alkyl groups from guanine bases, which can be 
introduced by carcinogens such as nitrosamides to protect cells against 
transition mutation. However, alkylating therapies including temozolomide and 
carmustine contained guanine bases which can be alkylated by MGMT protein 
leading to drug resistance (Silber et al. 1999). In 2005, Hegi and colleagues 
studied the correlation of MGMT promoter hypermethylation and response with 
temozolomide in 206 glioblastoma patients. Out of which, 92 patients had 
detectable MGMT promoter methylation while 114 did not have promoter 
MGMT methylation. The patients were subjected to temozolomide and 
radiotherapy. Interestingly, patients with MGMT methylation had a median 
progression free survival of 10.3 months compared to patients without MGMT 
methylation only had a median progression free survival of 5.3 months (Hegi et 
al. 2005). Overall, the study revealed that tumors without MGMT methylation 
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had little benefit from receiving alkylating agents and these patients will require 
alternative treatments that act on different mechanisms to inhibit MGMT. 
Another example of DNA methylation as an indicative predictor of drug 
response is the hypermethylation of TFAP2E in CRC. In 2012, a study 
conducted by Ebert, demonstrated that increased TFAP2E methylation 
corresponds to decrease TFAP2E expression followed by increased levels of 
DKK4 expression. It was observed that DKK4, a downstream target of TFAP2E 
when over expressed led to increased fluorouracil chemoresistance in CRC cell 
lines while introduction of TFAP2E increased the cells sensitivity to fluorouracil 
treatments. Overall, the study indicates that fluorouracil based chemotherapy is 
ineffective against patients with hypermethylation TFAP2E and high levels of 
DKK4 (Ebert et al. 2012). In order for these patients to receive effective 
treatments, alternative treatments should target on DKK4 to overcome TFAP2E 
mediated chemoresistance. In summary, the availability of epigenetic profiles 
in different cancers can increase the sensitivity and specificity of future 
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List of long range demethylated regions in CRC which overlapped with CTCF ChIA-PET loops 
 




chr1 179675000 179700000 25000 30.85% FAM163A 
chr10 81320000 81380000 60000 28.67% SFTPA2, SFTPA1 
chr11 96160000 96220000 60000 28.17% MAML2 
chr14 100450000 100485000 35000 27.74% EVL 
chr17 50185000 50220000 35000 27.56% CA10; MBTD1;UTP18 
chr19 42250000 42285000 35000 46.42% CEACAM5_CEACAM6 
chr2 171965000 172010000 45000 34.18% TLK1 
chr2 11725000 11790000 65000 31.20% Greb2 
chr2 57605000 57795000 190000 28.70% FANCL 
chr2 44710000 44740000 30000 27.21% LRPPRC; PPM1B; PREPL 
chr3 146355000 146500000 145000 28.07% zic1_4 
chr3 50920000 51050000 130000 24.86% DOCK3 
chr4 155550000 155650000 100000 28.64% RBM46_LRAT_FGG_FGA 
chr5 83225000 83595000 370000 29.51% EDIL3 




Gene ontology analysis of top 10% most upregulated and downregulated 
genes in colon tumor and metastasis 
 
Top 10% upregulated tumor genes   
Molecular and cellular functions P-value 
Cellular Growth and Proliferation  4.50E-17 - 3.64E-02  
Protein Synthesis  1.05E-15 - 3.16E-02  
Gene Expression  2.79E-14 - 3.64E-02  
Cell Death and Survival  1.60E-12 - 3.64E-02  
RNA Post-Transcriptional Modification  2.88E-09 - 3.64E-02 
    
Top 10% upregulated metastasis genes   
Molecular and cellular functions P-value 
Cellular Growth and Proliferation  2.87E-20 - 3.45E-02 
Cell Death and Survival   5.60E-13 - 3.56E-02 
Protein Synthesis  1.67E-12 - 3.12E-02 
RNA Post-Transcriptional Modification   2.83E-12 - 2.11E-02 
Gene Expression  1.02E-10 - 2.11E-02 
    
Top 10% downregulated tumor genes   
Molecular and cellular functions P-value 
Nucleic Acid Metabolism  1.03E-04 - 4.50E-02 
Small Molecule Biochemistry  1.03E-04 - 4.81E-02 
Cellular Development  1.21E-04 - 4.21E-02 
Cell Cycle 1.75E-04 - 4.04E-02 
Cell Signaling  1.83E-04 - 4.81E-02 
    
Top 10% downregulated metastasis genes   
Molecular and cellular functions P-value 
Cellular Development 5.42E-06 - 4.09E-02  
Cell-To-Cell Signaling and Interaction 4.31E-04 - 4.09E-02 
Cell Signaling 5.83E-04 - 4.65E-02  
Nucleic Acid Metabolism  5.83E-04 - 4.65E-02  
Small Molecule Biochemistry 5.83E-04 - 4.89E-02  
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Appendix C 
The percentage distribution of tumor and metastasis DMRs relative to the associated genomic features 
 
  tDMRs mDMRs 
  Hypermethylated Hypomethylated Hypermethylated Hypomethylated 
Promoter 17.20% 9.09% 64.09% 14.36%
Promoter W CGIs 8.20% 2.65% 60.80% 7.69% 
Promoter W/O CGIs 9.00% 6.44% 3.29% 6.67% 
Distal Promoter 9.20% 7.20% 6.16% 6.67% 
Distal Promoter W CGIs 0.80% 0.00% 5.01% 1.54% 
Distal Promoter W/O CGIs 8.40% 7.20% 1.15% 5.13% 
CGIs 14.00% 5.30% 87.89% 20.00% 
Genes  58.20% 50.38% 76.30% 58.97% 
Exons 10.80% 8.71% 9.03% 16.92% 
Introns 33.20% 34.47% 6.73% 29.23% 
Intergenic 28.60% 38.26% 12.21% 31.28% 
3' region 1.00% 2.27% 1.77% 1.54% 
MicroRNA 1.00% 0.38% 1.25% 0.51% 





List of MSP and BSP validation primers for CRC samples 
 
Bisulfite specific PCR primers 
Gene PCR regions Primer  Sequences 
SDC2 Chr8:97505843- 97506228  Forward 5' GGGTTTATTTGGGAGTTATATTGT 
   Reverse 5' AAAACTACTCTCTAAAACTCTTCTTACTCT 
WT1 Chr11:32457571-32457905 Forward 5' GTTTGGTTTTTGTTTTTAGAATTGT 
   Reverse 5' AAAATTTTCTTCCCTCCTAAACTAAC 
CDH4 Chr20:59826868-59827175 Forward 5' TGGAAATTTTTATTTTTGAGTTGTT 
   Reverse 5' CCAACCTCTACCCTCCTAAAC 
SPG20 Chr13:36920707-36921029 Forward 5' GTTTATTTTGATTTTTTAAATGGTA 
   Reverse 5' AAAATAATCAACCTTTATTATCTCTC 
ANPEP Chr15:90358073-90358289  Forward 5' TGTTTTTTTAGTATTGGATTTTTTTT 
   Reverse 5' ACCCTAATACATCCCAAACCC 
MPPED2 Chr11:30607902-30608231 Forward 5' ATAGGGATTGTTATTGGGGTTAAAG 
    Reverse 5' AAACTCCCTTCTTTTCCTAAAACAC
    
Methylation specific PCR primers   
Gene PCR regions Primer  Sequences 
ANPEP chr15:90358101- 90358455 M_Forward 5' TTCGTTTTTTTAAAGGGAAGTAATC 
   M_Reverse 5' ACCCGTCTACACGAAATACG 
   U_Forward 5' TTTGTTTTTTTAAAGGGAAGTAATTG 
   U_Reverse 5' ACCACCCATCTACACAAAATACACT 
MPPED2 chr11:30607926- 30608297 M_Forward 5' GGAGTATAGTTTTAGGAAGTAGGGC 
   M_Reverse 5' ACCTAACAAATCGATAAATAACGAA 
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   U_Forward 5' GGAGTATAGTTTTAGGAAGTAGGGTG 
   U_Reverse 5' AAACCTAACAAATCAATAAATAACAAA 
SFRP1 chr8:41284000-41286423 (Hg18) M_Forward 5' TCGGGTTTTTAGTTTTTAGTATCG 
   M_Reverse 5' ACTTAAATATAACAAATTCCCCGAA 
   U_Forward 5' TTGGGTTTTTAGTTTTTAGTATTGG 
    U_Reverse 5' ACTTAAATATAACAAATTCCCCAAA 
 
Appendix E 
List of tumor DMRs promoter associated genes with gene expression of ≥1.5 fold change 
 
tDMRs specific regions 
Z-




160084000 5.03 Promoter uc001fvb.2 ATP1A2 chr1:160080519-160111992 -2.65 
chr1:162590000-
162592000 5.46 Distal promoter uc001gcf.2 DDR2 chr1:162582227-162622227 -1.27 
chr1:27492000-27494000 5.03 Distal promoter uc001bnm.2 SLC9A1 chr1:27461451-27501451 -2.06 
chr1:33186000-33188000 6.14 Distal promoter uc001bvt.2 SYNC chr1:33148361-33188361 -1.13 
chr1:50575000-50577000 5.46 Promoter uc009vyu.2 ELAVL4 chr1:50570287-50668232 -0.75 
chr10:101188000-
101190000 5.71 Promoter uc001kpr.2 GOT1 chr10:101151627-101195530 -0.97 
chr11:120379000-
120381000 -5.42 Promoter uc001pxn.2 GRIK4 chr11:120377467-120861969 0.66 
chr11:75429000-75431000 5.12 Promoter uc001oww.1 MOGAT2 chr11:75423933-75445372 -0.90 
chr13:36044000-36047000 5.46 Promoter uc001uvb.2 NBEA chr13:35511455-36251872 -1.17 
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chr13:36052000-36054000 5.88 Promoter uc001uvb.2 NBEA chr13:35511455-36251872 -1.17 
chr16:15952000-15954000 5.46 Promoter uc002ddv.2 MYH11 chr16:15791993-15955887 -3.83 
chr16:88946000-88949000 6.48 Promoter uc002fmk.1 CBFA2T3 chr16:88936266-88952565 -0.63 
chr19:51329000-51331000 5.03 Promoter uc002ptk.1 KLK1 chr19:51317403-51332043 -0.80 
chr2:103237000-
103239000 5.29 Promoter uc002tca.2 SLC9A2 chr2:103231165-103332807 -0.84 
chr2:189821000-
189823000 -5.34 Distal promoter uc002uqj.1 COL3A1 chr2:189819098-189859098 1.14 
chr2:86582000-86584000 5.29 Distal promoter uc002srh.3 REEP1 chr2:86544777-86584777 -1.09 
chr20:9284000-9286000 -5.34 Promoter uc010gbw.1 PLCB4 chr20:9044700-9443136 0.80 
chr3:148949000-
148951000 5.12 Distal promoter uc011bnr.1 CP chr3:148919832-148959832 -0.80 
chr5:174170000-
174172000 -5.08 Distal promoter uc003mcy.2 MSX2 chr5:174131574-174171574 1.62 
chr8:58899000-58901000 5.88 Distal promoter uc003xtj.1 FAM110B chr8:58887112-58927112 -0.81 
chrX:100806000-





List of metastasis DMRs genes with differential gene expression ≥1.5 fold change 
mDMRs specific regions 
Z- 
score Gene features UCSC ID Gene symbol Gene region 
Log ratio 
(M/N) 
chr1:200841000-200844000 8.27 Promoter uc001gvn.1 GPR25 chr1:200837165-200848251 -0.66 
chr1:207668000-207671000 6.22 Promoter uc001hfv.2 CR2 chr1:207622669-207668238 -3.01 
chr1:220100000-220103000 7.43 Promoter uc001hlw.2 SLC30A10 chr1:220082606-220106993 -1.63
chr1:221049000-221052000 5.02 Promoter uc001hmv.3 HLX chr1:221047742-221063398 -0.75 
chr1:221054000-221059000 6.44 Promoter uc001hmv.3 HLX chr1:221047742-221063398 -0.75 
chr1:226924000-226927000 9.76 Promoter uc010pvo.1 ITPKB chr1:226814391-226931876 -1.48 
chr1:244217000-244219000 -5.019 Promoter uc001iaf.1 ZNF238 chr1:244212097-244224193 0.59 
chr1:248020000-248022000 8.84 Promoter uc001ido.2 TRIM58 chr1:248015500-248048436 -1.35 
chr1:49241000-49244000 6.86 Promoter uc001crx.3 BEND5 chr1:49188541-49247547 -0.89 
chr1:66257000-66260000 7.64 Promoter uc001dcn.2 PDE4B chr1:66253192-66845261 -1.24 
chr1:78956000-78958000 6.29 Promoter uc001dim.2 PTGFR chr1:78951727-79011385 -2.86 
chr10:102278000-102281000 8.77 Promoter uc010qpo.1 SEC31B chr10:102241402-102281754 -0.90 
chr10:118030000-118035000 13.15 Promoter uc001lci.2 GFRA1 chr10:117811443-118036819 -0.67 
chr10:119000000-119002000 5.30 Promoter uc001ldd.1 SLC18A2 chr10:118995715-119042095 -1.78 
chr10:125850000-125853000 5.30 Promoter uc001lhm.2 CHST15 chr10:125762185-125856930 -1.14
chr10:15760000-15763000 8.84 Promoter uc001ioc.1 ITGA8 chr10:15554087-15766770 -0.85
chr10:43599000-43602000 5.52 Promoter uc001jak.1 RET chr10:43567516-43627952 -0.62 
chr10:50322000-50325000 8.06 Promoter uc001jhf.2 C10orf72 chr10:50217332-50328559 -1.16 
chr10:7707000-7710000 7.43 Promoter uc001ijq.2 ITIH5 chr10:7596635-7713934 -2.83 
chr10:81002000-81004000 5.80 Promoter uc001kaf.2 ZMIZ1 chr10:80823791-81081285 -0.72 
chr10:93392000-93394000 5.73 Promoter uc001kho.2 PPP1R3C chr10:93383200-93397858 -1.46 
chr11:104033000-104036000 5.09 Promoter uc001php.2 PDGFD chr11:103772914-104040027 -0.80 
chr11:124621000-124623000 6.22 Promoter uc001qaq.2 NRGN chr11:124604828-124622102 -0.59 
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chr11:130297000-130299000 5.23 Promoter uc001qgg.3 ADAMTS8 chr11:130269819-130303539 -1.00 
chr11:133938000-133941000 8.13 Promoter uc001qhb.1 JAM3 chr11:133933819-134026649 -1.20 
chr11:1885000-1887000 6.29 Promoter uc001lui.2 LSP1 chr11:1869199-1918492 -1.40 
chr11:30605000-30608000 8.42 Promoter uc009yji.2 MPPED2 chr11:30,431,618-30,605,750 -1.23 
chr11:60718000-60721000 9.90 Promoter uc001nqn.2 SLC15A3 chr11:60699554-60724257 -1.10 
chr11:66624000-66626000 -5.233 Promoter uc001ojq.1 LRFN4 chr11:66,624,589-66,626,357 1.21 
chr12:1772000-1774000 5.59 Promoter uc009zdq.2 WNT5B chr12:1663822-1776377 -1.77 
chr12:22486000-22489000 8.91 Promoter uc001rfo.3 ST8SIA1 chr12:22341325-22492648 -1.68 
chr12:41581000-41584000 5.80 Promoter uc010skn.1 PDZRN4 chr12:41577786-41973384 -1.99
chr12:5152000-5155000 9.62 Promoter uc001qni.2 KCNA5 chr12:5148084-5160948 -0.64 
chr12:66582000-66584000 5.66 Promoter uc001stg.2 IRAK3 chr12:66577977-66596997 -0.78 
chr12:7167000-7169000 5.12 Promoter uc001qsj.2 C1S  chr12:7,096,260-7,178,335 -1.18 
chr13:36871000-36873000 5.38 Promoter uc010tei.1 SOHLH2 chr13:36737346-36876992 -0.98 
chr13:96295000-96298000 8.27 Promoter uc001vmk.2 DZIP1 chr13:96225456-96301957 -1.41 
chr14:103989000-103991000 5.59 Promoter uc001yne.1 CKB chr14:103980995-103993021 -1.41 
chr14:23820000-23822000 5.45 Promoter uc001wjl.2 SLC22A17 chr14:23810527-23826660 -0.95 
chr14:27066000-27069000 5.16 Promoter uc001wpy.2 NOVA1 chr14:26910089-27071960 -1.16 
chr14:38678000-38681000 6.37 Promoter uc010amu.1 SSTR1 chr14:38673280-38686052 -0.63 
chr14:51560000-51562000 6.44 Promoter uc001wyx.3 TRIM9 chr14:51436981-51567422 -1.30 
chr14:53416000-53418000 5.73 Promoter uc001xad.2 FERMT2 chr14:53318989-53422591 -1.77 
chr14:65007000-65010000 11.10 Promoter uc001xhj.2 HSPA2 chr14:64997622-65014952 -2.08 
chr15:101419000-101422000 5.30 Promoter uc010bpa.1 ALDH1A3 chr15:101415008-101437442 -1.39 
chr15:33602000-33605000 10.18 Promoter uc001zhi.2 RYR3 chr15:33598176-34163302 -1.10 
chr15:37386000-37389000 6.37 Promoter uc001zjl.2 MEIS2 chr15:37178232-37395503 -2.16 
chr15:37394000-37396000 5.02 Promoter uc001zjl.2 MEIS2 chr15:37178232-37395503 -2.16 
chr15:45669000-45672000 12.87 Promoter uc001zvb.2 GATM chr15:45648323-45675742 -0.63
chr15:65368000-65371000 5.52 Promoter uc010uir.1 RASL12 chr15:65,345,675-65,369,028 -1.00
chr15:78912000-78914000 8.35 Promoter uc002bea.2 CHRNA3 chr15:78880396-78918322 -0.82 
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chr15:83314000-83318000 5.16 Promoter uc010uof.1 CPEB1 chr15:83206951-83321356 -0.72 
chr15:84321000-84325000 9.19 Promoter uc002bjy.1 ADAMTSL3 chr15:84317837-84536431 -1.75 
chr15:90356000-90358000 5.36 Promoter uc002bop.3 ANPEP chr15:90,328,126-90,358,072 -2.91 
chr16:1202000-1205000 7.21 Promoter uc002cks.2 CACNA1H chr16:1198240-1276771 -1.33 
chr16:23847000-23849000 6.65 Promoter uc002dmd.2 PRKCB chr16:23842299-24236930 -2.48 
chr16:4587000-4590000 8.20 Promoter uc002cwv.2 C16orf5 chr16:4555678-4593471 -0.96 
chr16:79632000-79634000 5.66 Promoter uc002ffm.2 MAF chr16:79622745-79639622 -1.37 
chr17:10100000-10103000 7.28 Promoter uc002gmg.1 GAS7 chr17:9808925-10106868 -1.11 
chr17:46618000-46620000 8.27 Promoter uc002inm.2 HOXB2 chr17:46615020-46627393 -0.60
chr17:46618000-46621000 8.27 Promoter uc002inm.2 HOXB2  chr17:46,620,019-46,622,393  -0.60 
chr18:11751000-11753000 9.76 Promoter uc002kqc.2 GNAL chr18:11684135-11888144 -0.99 
chr18:49867000-49869000 5.30 Promoter uc002lfe.1 DCC chr18:49861570-51062782 -0.62 
chr18:499000-502000 6.72 Promoter uc002kkm.2 COLEC12 chr18:314355-505729 -1.37 
chr18:52989000-52991000 5.94 Promoter uc002lfw.3 TCF4 chr18:52884561-52994036 -0.85 
chr18:53254000-53257000 5.30 Promoter uc010xdx.1 TCF4 chr18:52884561-53258336 -0.85 
chr18:5542000-5545000 5.80 Promoter uc010wzh.1 EPB41L3 chr18:5387387-5545555 -3.49 
chr18:5629000-5631000 6.44 Promoter uc010dkq.1 EPB41L3 chr18:5387387-5633990 -3.49 
chr18:7567000-7570000 7.99 Promoter uc010dkv.2 PTPRM chr18:7562313-8411858 -0.99 
chr19:16436000-16439000 9.76 Promoter uc002ndw.2 KLF2 chr19:16430650-16443337 -1.25 
chr19:37095000-37098000 8.49 Promoter uc010xth.1 ZNF529 chr19:37029517-37101178 -0.64 
chr19:58628000-58631000 6.58 Promoter uc010yht.1 ZSCAN18 chr19:58590208-58634793 -0.78 
chr2:127413000-127415000 6.22 Promoter uc002tnq.2 GYPC chr2:127408683-127459245 -1.74 
chr2:145272000-145276000 5.09 Promoter uc002tvu.2 ZEB2 chr2:145140584-145282916 -1.14 
chr2:149632000-149635000 7.36 Promoter uc010zbu.1 KIF5C chr2:149627818-149888273 -0.89 
chr2:161263000-161266000 12.16 Promoter uc002ubl.2 RBMS1 chr2:161123662-161269400 -0.82 
chr2:182321000-182324000 11.81 Promoter uc002unt.2 ITGA4 chr2:182316618-182329095 -1.32
chr2:183731000-183733000 6.08 Promoter uc002upa.1 FRZB chr2:183693736-183736498 -1.58
chr2:202899000-202902000 7.07 Promoter uc002uyw.1 FZD7 chr2:202894309-202908160 -0.81 
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chr2:26915000-26917000 7.07 Promoter uc002rhn.2 KCNK3 chr2:26910580-26959066 -1.20 
chr2:29337000-29340000 13.58 Promoter uc002rmu.2 CLIP4 chr2:29315570-29402578 -0.64 
chr2:40678000-40681000 10.82 Promoter uc002rsa.2 SLC8A1 chr2:40334286-40684209 -0.75 
chr2:50573000-50576000 10.75 Promoter uc010fbp.2 NRXN1 chr2:50140643-50579894 -1.41 
chr2:72373000-72376000 6.37 Promoter uc010yra.1 CYP26B1 chr2:72351366-72376544 -2.44 
chr2:80529000-80531000 5.30 Promoter uc010yse.1 CTNNA2 chr2:79407356-80880904 -0.77 
chr2:95689000-95692000 5.16 Promoter uc002stx.1 MAL chr2:95686478-95724735 -1.30 
chr2:98962000-98965000 7.78 Promoter uc002syt.2 CNGA3 chr2:98957617-99020057 -0.97 
chr20:21492000-21494000 5.87 Promoter uc002wsi.2 NKX2-2 chr20:21486663-21499664 -1.94
chr20:30639000-30642000 5.16 Promoter uc002wxh.2 HCK chr20:30635056-30694655 -0.72 
chr20:39316000-39318000 8.63 Promoter uc002xji.2 MAFB chr20:39309518-39322876 -1.03 
chr20:39318000-39321000 6.15 Promoter uc002xji.2 MAFB chr20:39309518-39322876 -1.03 
chr20:42743000-42746000 5.87 Promoter uc002xli.1 JPH2 chr20:42735336-42821218 -0.76 
chr20:61275000-61277000 -5.019 Promoter uc002ydb.1 SLCO4A1 chr20:61268796-61308647 2.13 
chr20:61339000-61342000 13.65 Promoter uc002ydf.2 NTSR1 chr20:61335188-61399122 -0.73 
chr20:62678000-62681000 8.77 Promoter uc002yhs.2 SOX18 chr20:62674080-62685979 -0.75 
chr21:19616000-19619000 6.93 Promoter uc002ykr.2 CHODL chr21:19268579-19644685 -1.37 
chr21:46929000-46931000 -5.514 Promoter uc002zhg.2 COL18A1 chr21:46820096-46938633 0.79 
chr21:47517000-47520000 5.73 Promoter uc002zhy.1 COL6A2 chr21:47513032-47554719 -1.37 
chr22:29875000-29878000 9.62 Promoter uc003afo.2 NEFH chr22:29871180-29892275 -0.75 
chr22:31480000-31482000 5.52 Promoter uc003ajk.1 SMTN chr22:31472304-31505609 -1.32 
chr3:115341000-115344000 7.85 Promoter uc003ebr.2 GAP43 chr3:115337150-115445334 -0.78 
chr3:148414000-148417000 6.79 Promoter uc003ewg.2 AGTR1 chr3:148410657-148465788 -1.16 
chr3:156008000-156011000 5.59 Promoter uc003far.2 KCNAB1 chr3:155833336-156261927 -1.08 
chr3:164912000-164915000 7.50 Promoter uc003fej.3 SLITRK3 chr3:164899517-164918790 -1.03 
chr3:173114000-173117000 6.79 Promoter uc003fio.1 NLGN1 chr3:173111243-174006116 -1.56
chr3:187387000-187389000 7.71 Promoter uc003frn.2 SST chr3:187381695-187393201 -2.21
chr3:238000-241000 9.62 Promoter uc003bot.2 CHL1 chr3:233649-456095 -4.03 
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chr3:33259000-33262000 7.71 Promoter uc003cfo.1 SUSD5 chr3:33186536-33265707 -0.76 
chr3:38035000-38037000 5.80 Promoter uc003chj.2 VILL chr3:38024529-38053675 -1.13 
chr3:87039000-87041000 6.51 Promoter uc003dqn.2 VGLL3 chr3:86982124-87045257 -0.88 
chr4:104640000-104642000 5.16 Promoter uc003hxe.1 TACR3 chr4:104505624-104645973 -1.20 
chr4:123746000-123749000 5.23 Promoter uc003iev.1 FGF2 chr4:123742862-123824390 -1.76 
chr4:126236000-126240000 5.23 Promoter uc003ifj.3 FAT4 chr4:126232566-126419086 -1.89 
chr4:13544000-13546000 6.93 Promoter uc003gmx.2 NKX3-2 chr4:13537453-13551114 -2.24 
chr4:156296000-156299000 7.43 Promoter uc003ios.2 MAP9 chr4:156258813-156303122 -1.34 
chr4:156587000-156591000 10.11 Promoter uc003iou.2 GUCY1A3 chr4:156582861-156637533 -0.88
chr4:156679000-156683000 8.49 Promoter uc003ipc.2 GUCY1B3 chr4:156675125-156733782 -0.64 
chr4:176922000-176924000 5.52 Promoter uc003iug.2 GPM6A chr4:176549088-176928648 -3.41 
chr4:20254000-20258000 6.22 Promoter uc003gpr.1 SLIT2 chr4:20250234-20625788 -0.77 
chr4:41257000-41260000 5.94 Promoter uc003gvo.2 UCHL1 chr4:41253897-41275445 -1.45 
chr4:41746000-41751000 6.86 Promoter uc003gwf.3 PHOX2B chr4:41741099-41755987 -0.64 
chr4:90823000-90825000 5.20 Promoter uc010iku.2 MMRN1 chr4:90,816,003-90,875,780  -2.04 
chr5:134913000-134916000 7.14 Promoter uc003lay.2 CXCL14 chr5:134901372-134919969 -2.52 
chr5:146888000-146891000 6.65 Promoter uc003loo.2 DPYSL3 chr5:146765370-146894424 -1.09 
chr5:15499000-15502000 7.00 Promoter uc003jfn.1 FBXL7 chr5:15495304-15944900 -0.81 
chr5:168726000-168729000 6.29 Promoter uc003mab.2 SLIT3 chr5:168088071-168733133 -1.46 
chr5:38555000-38558000 9.05 Promoter uc010ive.1 LIFR chr5:38470064-38561748 -1.00 
chr5:7395000-7397000 6.22 Promoter uc003jdz.1 ADCY2 chr5:7391342-7835194 -0.71 
chr5:76505000-76508000 5.87 Promoter uc003kfa.2 PDE8B chr5:76501705-76728226 -0.70 
chr5:79330000-79332000 7.78 Promoter uc003kgh.2 THBS4 chr5:79325990-79384105 -1.88 
chr5:88184000-88187000 8.20 Promoter uc003kjj.2 MEF2C chr5:88009057-88184302 -1.34 
chr6:151561000-151563000 5.73 Promoter uc011eep.1 AKAP12 chr6:151556133-151684692 -2.15 
chr6:39760000-39762000 5.04 Promoter uc003oov.3 DAAM2 chr6:39,760,159-39,872,653 -1.27
chr6:80656000-80659000 9.76 Promoter uc003pja.3 ELOVL4 chr6:80619535-80662315 -1.29
chr6:88875000-88878000 6.44 Promoter uc010kbz.2 CNR1 chr6:88844586-88877742 -0.73 
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 chr7:153748000-153751000 6.37 Promoter uc003wli.2 DPP6 chr7:153579418-154690994 -0.76 
chr7:15724000-15727000 7.43 Promoter uc003stc.2 MEOX2 chr7:15645838-15731308 -1.41 
chr7:50342000-50345000 8.91 Promoter uc003tov.1 IKZF1 chr7:50339377-50442142 -0.87 
chr7:94291000-94293000 5.02 Promoter uc003uno.2 PEG10 chr7:94280636-94304004 -1.62 
chr7:97360000-97364000 8.91 Promoter uc003uop.3 TAC1 chr7:97356270-97374782 -1.43 
chr8:116679000-116681000 5.73 Promoter uc011lhy.1 TRPS1 chr8:116415724-116685234 -0.91 
chr8:121136000-121139000 5.52 Promoter uc003yox.2 COL14A1 chr8:121132351-121389266 -0.94 
chr8:32404000-32408000 5.52 Promoter uc003xip.2 NRG1 chr8:31492267-32605768 -0.62 
chr8:59057000-59060000 5.52 Promoter uc003xtj.1 FAM110B chr8:58902112-59067277 -1.77
chr8:98289000-98291000 9.19 Promoter uc003yhy.2 TSPYL5 chr8:98280714-98295176 -1.12 
chr9:110248000-110252000 6.37 Promoter uc004bdf.1 KLF4 chr9:110242134-110255728 -2.42 
chr9:124131000-124134000 10.89 Promoter uc004blh.2 STOM chr9:124096353-124137545 -0.92 
chr9:124981000-124984000 10.32 Promoter uc010mvw.2 LHX6 chr9:124959859-124994865 -1.41 
chr9:124987000-124990000 7.92 Promoter uc010mvw.2 LHX6 chr9:124959859-124994865 -1.41 
chr9:13278000-13281000 10.54 Promoter uc003zlb.3 MPDZ chr9:13100708-13284563 -0.86 
chr9:137966000-137968000 7.64 Promoter uc010naq.1 OLFM1 chr9:137962088-137974235 -1.85 
chr9:137978000-137981000 5.16 Promoter uc004cfk.3 OLFM1 chr9:137962088-137994951 -1.85 
chr9:139879000-139881000 5.30 Promoter uc004ckd.2 PTGDS chr9:139864545-139881193 -1.98 
chr9:89559000-89562000 5.87 Promoter uc004aox.3 GAS1 chr9:89554278-89567104 -1.82 
chrX:101905000-101907000 5.87 Promoter uc004ejj.3 GPRASP1 chrX:101901293-101919008 -0.84 
chrX:119442000-119445000 7.00 Promoter uc004eso.3 FAM70A chrX:119387505-119450391 -1.36 
chrX:12155000-12158000 5.23 Promoter uc004cuz.1 FRMPD4 chrX:12151584-12745529 -0.61 
chrX:140270000-140272000 7.07 Promoter uc004fbj.2 LDOC1 chrX:140264939-140276310 -0.65 
chrX:51238000-51240000 6.22 Promoter uc010njt.2 NUDT11 chrX:51227871-51244459 -1.29 
chrX:6143000-6146000 5.66 Promoter uc010ndh.2 NLGN4X chrX:5803083-6150116 -3.67 
chrX:72434000-72436000 5.52 Promoter uc011mqj.1 NAP1L2 chrX:72427491-72439668 -2.52
chrX:92928000-92930000 5.02 Promoter uc004efq.2 NAP1L3 chrX:92920928-92933608 -1.62
